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Background: Infections acquired in hospital are an important cause of morbidity and mortality in very
preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm
infants with lactoferrin, an antimicrobial protein processed from cow’s milk, prevents infections and
associated complications.
Objective: To determine whether or not enteral supplementation with bovine lactoferrin (The Tatua
Cooperative Dairy Company Ltd, Morrinsville, New Zealand) reduces the risk of late-onset infection
(acquired > 72 hours after birth) and other morbidity and mortality in very preterm infants.
Design: Randomised, placebo-controlled, parallel-group trial. Randomisation was via a web-based portal
and used an algorithm that minimised for recruitment site, weeks of gestation, sex and single versus
multiple births.
Setting: UK neonatal units between May 2014 and September 2017.
Participants: Infants born at < 32 weeks’ gestation and aged < 72 hours at trial enrolment.
Interventions: Eligible infants were allocated individually (1 : 1 ratio) to receive enteral bovine lactoferrin
(150 mg/kg/day; maximum 300 mg/day) or sucrose (British Sugar, Peterborough, UK) placebo (same dose)
once daily from trial entry until a postmenstrual age of 34 weeks. Parents, caregivers and outcome
assessors were unaware of group assignment.
Outcomes: Primary outcome – microbiologically confirmed or clinically suspected late-onset infection.
Secondary outcomes – microbiologically confirmed infection; all-cause mortality; severe necrotising
enterocolitis (NEC); retinopathy of prematurity (ROP); bronchopulmonary dysplasia (BPD); a composite of
infection, NEC, ROP, BPD and mortality; days of receipt of antimicrobials until 34 weeks’ postmenstrual age;
length of stay in hospital; and length of stay in intensive care, high-dependency and special-care settings.
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Results: Of 2203 enrolled infants, primary outcome data were available for 2182 infants (99%). In the
intervention group, 316 out of 1093 (28.9%) infants acquired a late-onset infection versus 334 out of 1089
(30.7%) infants in the control group [adjusted risk ratio (RR) 0.95, 95% confidence interval (CI) 0.86 to 1.04].
There were no significant differences in any secondary outcomes: microbiologically confirmed infection
(RR 1.05, 99% CI 0.87 to 1.26), mortality (RR 1.05, 99% CI 0.66 to 1.68), NEC (RR 1.13, 99% CI 0.68 to
1.89), ROP (RR 0.89, 99% CI 0.62 to 1.28), BPD (RR 1.01, 99% CI 0.90 to 1.13), or a composite of infection,
NEC, ROP, BPD and mortality (RR 1.01, 99% CI 0.94 to 1.08). There were no differences in the number of
days of receipt of antimicrobials, length of stay in hospital, or length of stay in intensive care, high-dependency
or special-care settings. There were 16 reports of serious adverse events for infants in the lactoferrin group
and 10 for infants in the sucrose group.
Conclusions: Enteral supplementation with bovine lactoferrin does not reduce the incidence of infection,
mortality or other morbidity in very preterm infants.
Future work: Increase the precision of the estimates of effect on rarer secondary outcomes by combining
the data in a meta-analysis with data from other trials. A mechanistic study is being conducted in a
subgroup of trial participants to explore whether or not lactoferrin supplementation affects the intestinal
microbiome and metabolite profile of very preterm infants.
Trial registration: Current Controlled Trials ISRCTN88261002.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 74.
See the NIHR Journals Library website for further project information. This trial was also sponsored by the
University of Oxford, Oxford, UK. The funder provided advice and support and monitored study progress
but did not have a role in study design or data collection, analysis and interpretation.
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Plain English summary
Babies who are born ‘very prematurely’ (i.e. > 8 weeks early) need specialist hospital care on a neonatalunit. These babies can develop serious infections and illnesses during their stay in hospital. The risk
of developing such infections is highest in the most premature infants.
This study was designed to test whether or not giving lactoferrin (The Tatua Cooperative Dairy Company Ltd,
Morrinsville, New Zealand), a naturally occurring milk protein (often used as a food supplement), to babies
can help to protect them against infections. A small study was previously carried out in Italy and, although
the results were promising, we needed to find out more. A large study was undertaken in neonatal units
across the UK. More than 2200 very premature babies took part to find out whether or not lactoferrin is
effective at preventing infections and other illnesses. With consent from babies’ parents, clinicians randomly
(by chance) allocated babies to receive either lactoferrin or sugar (sham treatment) mixed with milk once a
day until they were no longer at a high risk of serious infections (the equivalent of 34 weeks’ gestation).
The babies’ parents, nurses and doctors were not aware of whether each individual baby was receiving
lactoferrin or sucrose (British Sugar, Peterborough, UK).
When all of the study data had been analysed, it was found that supplemental lactoferrin did not reduce
the risk of infection or other serious illness or death, or affect the length of hospital stay, in very premature
babies born > 8 weeks early. Because the study was large and used reliable methods, these results prove
that lactoferrin supplementation does not have important benefits for very premature babies and that
there is no need for any further research into the use of this treatment.
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Scientific summary
Background
Late-onset infection is the most common serious complication associated with hospital care for preterm 
infants. The reported incidence ranges from about 15% to 30% in very preterm infants, reflecting their high 
levels of exposure to invasive procedures and intensive care. Very preterm infants with late-onset infection 
have a higher rate of mortality and morbidities, such as bronchopulmonary dysplasia (BPD), necrotising 
enterocolitis (NEC) and retinopathy of prematurity (ROP), than infants without infections. Given this burden 
of mortality, morbidity and the associated costs for families and health services, the James Lind Alliance 
Preterm Birth Priority Setting Partnership (Southampton, UK) has identified the development and assessment 
of better methods to prevent infection in preterm infants as a research priority. One such promising 
intervention is enteral supplementation with the processed cow’s milk protein, lactoferrin (The Tatua 
Cooperative Dairy Company Ltd, Morrinsville, New Zealand).
Lactoferrin is the major whey protein in breast milk and is a key component of the mammalian innate 
response to infection. It has broad microbiocidal activity via mechanisms, such as cell membrane disruption, 
iron sequestration, the inhibition of microbial adhesion to host cells and the prevention of biofilm formation. 
Lactoferrin has prebiotic properties, promoting the growth of beneficial bacteria and reducing colonisation 
by pathogenic species. It enhances intestinal mucosal integrity and immune function by modulating cytokine 
expression, suppressing free-radical activity and activating and mobilising leucocytes.
Bovine lactoferrin is 70% homologous with human lactoferrin, but has a higher antimicrobial activity. It has 
been a component of the human infant diet for thousands of years, is available as a food supplement in a 
powder form and is registered as ‘Generally Recognised as Safe’ by the US Federal Drug Administration.
The Cochrane review of lactoferrin supplementation for preterm infants includes six randomised controlled 
trials (RCTs) with 1071 participants in total (Pammi M, Suresh G. Enteral lactoferrin supplementation for 
prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2017;6: 
CD007137). Meta-analyses suggest that lactoferrin reduces the incidence of late-onset invasive infection by 
about 40%. The effect size is similar whether infants are fed human milk or formula. The risk of NEC is 
decreased by about 60%. No evidence of adverse effects or intolerance exists. As the included trials were 
small and contained various methodological weaknesses, the evidence was considered to be of low quality 
and the review concluded that data from high-quality trials were needed to provide evidence of sufficient 
validity to inform policy and practice.
Objective
To assess the effect of enteral supplementation with bovine lactoferrin on the risk of late-onset infection 
and other morbidity and mortality in very preterm infants.
Methods
Study design
The Enteral Lactoferrin In Neonates (ELFIN) trial: a multicentre, randomised, placebo-controlled, parallel-group 
trial of prophylactic enteral lactoferrin supplementation to prevent late-onset invasive infection in very preterm 
infants (see www.npeu.ox.ac.uk/elfin).
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Setting
Neonatal units in UK hospitals; participant recruitment and initial care in 37 units and continuing care during
birth hospitalisation in a further 97 units.
Participants
Very preterm infants of < 72 hours old at randomisation. Infants with a severe congenital anomaly, without
a realistic prospect of survival or who were likely to be fasted enterally for > 14 days were ineligible to
participate. Written consent was sought from parents only after they had received a verbal and written
explanation of the trial.
Interventions
Infants were allocated individually via a secure web-based randomisation portal in the ratio of 1 : 1, minimised
for recruiting site, sex, gestational age at birth (completed weeks) and single versus multiple births, to receive
either (1) bovine lactoferrin (150mg/kg/day, up to a maximum of 300 mg/day) or (2) sucrose (British Sugar,
Peterborough, UK) placebo (at the same dose). The lactoferrin powder or sucrose was mixed in sterile water
plus either expressed breast milk or formula prior to administration via a nasogastric or orogastric tube or
orally. The intervention was commenced when the infant’s enteral feed volume reached 12ml/kg/day and
was continued once daily until the infant reached 34 weeks’ postmenstrual age. Parents, clinicians, carers and
those assessing the outcomes were unaware of group assignment.
Outcomes
Primary outcome
Microbiologically confirmed or clinically suspected late-onset infection (occurring > 72 hours after birth)
from trial entry until hospital discharge.
Secondary outcomes
Microbiologically confirmed infection; all-cause mortality; severe NEC (Bell’s stage II or III); ROP treated
surgically or medically; BPD (receipt of supplemental oxygen or respiratory support at 36 weeks’
postmenstrual age); a composite of infection, NEC, ROP, BPD and mortality; days of administration of
antimicrobials until 34 weeks’ postmenstrual age; duration of birth hospitalisation; and length of stay in
intensive care, high-dependency care or special-care settings.
Statistics and analysis plan
Sample size
Calculations were based on a primary outcome event rate range of 18% to 24%. In summary, with 90%
power and a two-sided 5% significance level, to detect an absolute risk reduction of 5–5.8% (relative risk
reduction of 24–28%) required a trial with a total of up to 2200 participants (allowing for an anticipated
loss to follow-up of up to 5%). This sample size was sufficient to exclude important effects on secondary
outcomes with 90% power.
Statistical analyses
Demographic factors and clinical characteristics at randomisation were summarised with counts (%) for
categorical variables, mean (standard deviation) for normally distributed continuous variables or median
[interquartile range (IQR)] for other continuous variables.
Outcomes for participants were analysed in the groups to which they were assigned, regardless of deviation
from the protocol or treatment received. Comparative analyses calculated the relative risk ratio (RR) with
95% confidence interval (CI) for the primary outcome (99% CIs for all other dichotomous outcomes), the
mean difference (99% CI) for normally distributed continuous outcomes or the median difference (99% CI)
for skewed continuous variables.
SCIENTIFIC SUMMARY
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The groups were compared using regression analysis adjusting for the minimisation factors (recruiting hospital,
sex, weeks’ gestation at birth and single vs. multiple births) to account for the correlation between treatment
groups introduced by balancing the randomisation. The crude unadjusted and adjusted estimates were
calculated with the primary inference to be based on the adjusted analysis.
The consistency of the effect of lactoferrin supplementation on the primary outcome across specific subgroups
of infants was assessed using the statistical test of interaction. Prespecified subgroups were (1) completed
weeks’ gestation at birth and (2) infants given human breast milk versus formula versus both human milk and
formula during the trial period.
Results
The internal pilot was undertaken from May 2014 for 12 months in six neonatal units; 90 infants were
recruited to participate. The main trial recruitment period ran from July 2015 to September 2017 in
37 neonatal units. In total, the trial recruited 2203 infants; 1099 infants were allocated to receive bovine
lactoferrin and 1104 were allocated to receive sucrose placebo. Four infants had consent withdrawn or
unconfirmed. In total, 1098 infants in the lactoferrin group and 1101 in the sucrose group were included
in the intention-to-treat analyses.
Baseline characteristics were well balanced. The median gestation age at birth was 29 weeks in both groups
(37% aged < 28 weeks). The median birthweight was 1126 g in the lactoferrin group and 1143 g in the
placebo group. Overall, 91% of infants were exposed to antenatal corticosteroid, 57% were born via
caesarean section, 25% were born following rupture of maternal amniotic membranes for > 24 hours and
12% had evidence of absent or reverse end diastolic flow in the fetal umbilical artery.
Primary outcome
Data were available for 2182 infants (99%). In the intervention group, 316 out of 1093 (28.9%) infants
acquired a microbiologically confirmed or clinically suspected late-onset infection, compared with 334 out
of 1089 (30.7) in the control group (adjusted RR 0.95, 95% CI 0.86 to 1.04).
Secondary outcomes
There were no significant differences in rates of:
l microbiologically confirmed infection: RR 1.05 (99% CI 0.87 to 1.26)
l all-cause mortality until hospital discharge: RR 1.05 (99% CI 0.66 to 1.68)
l NEC: RR 1.13 (99% CI 0.68 to 1.89)
l ROP: RR 0.89 (99% CI 0.62 to 1.28)
l BPD: RR 1.01 (99% CI 0.90 to 1.13)
l a composite of infection, NEC, ROP, BPD and mortality: RR 1.01 (99% CI 0.94 to 1.08).
There were no differences in the median number of days of receipt of:
l antimicrobials: median difference 0 (99% CI –1 to 1)
l hospital care: median difference 1 (99% CI –1 to 3)
l intensive care: median difference 0 (99% CI –1 to 1)
l high-dependency care: median difference 1 (99% CI –1 to 3)
l special care: median difference –1 (99% CI –3 to 1).
Subgroup analyses did not show any significant interactions for:
l completed weeks’ gestation at birth: p = 0.273
l type of enteral milk received (human, formula, or both): p = 0.400.
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Safety and adverse events
There were 16 serious adverse events (SAEs) reported for infants in the lactoferrin group (six severe) and
10 for infants in the sucrose group (three severe). Two SAEs, both in the lactoferrin group, were assessed
as being ‘possibly related’ to the trial intervention. The remaining 24 SAEs were considered to be unrelated
to the trial intervention.
Discussion
The ELFIN trial shows that enteral supplementation of bovine lactoferrin (150 mg/kg/day until 34 weeks’
postmenstrual age) does not reduce the risk of late-onset infection, other morbidity or mortality in very
preterm infants. This contradicts the existing trial evidence. The current Cochrane review includes six RCTs
and meta-analyses that suggest substantial reductions in the risk of late-onset infection and NEC associated
with lactoferrin supplementation in very preterm infants. The included trials were small and some contained
other design and methodological weaknesses that may have introduced biases, thus resulting in overestimation
of the effect sizes. The largest previous trial, in which 331 infants participated, showed a relative risk reduction
of 66% for late-onset infection. This effect size estimate may have been inflated by performance and detection
bias, and by methodological weaknesses, including the absence of predefined criteria for interim analyses.
Given these concerns, the Cochrane review graded the quality of the existing evidence for effects on key
outcomes as ‘low’ and concluded that data from methodologically rigorous RCTs were needed to generate
evidence of sufficient validity to inform policy and practice.
The ELFIN trial provides these data. The validity of the findings is enhanced by the methodological quality
and power of the trial. Best practices were used to limit bias, including central web-based randomisation
for allocation concealment, blinding of parents, caregivers and investigators to the group allocation,
and intention-to-treat analyses of outcomes based on a prespecified statistical analysis plan. The trial
recruited > 2200 participants as per protocol and a priori sample size estimation. Demographic and
prognostic characteristics were well-balanced between the two groups at randomisation with a minimisation
algorithm, ensuring balance for known or putative prognostic indicators (completed weeks’ gestation, sex,
single vs. multiple births) or potential confounding influences (recruiting site). Interim analyses by the trial’s
independent Data Monitoring Committee (DMC) used criteria to minimise the chances of spurious findings
caused by data fluctuations before a sufficient sample size was achieved. Adherence to the allocated
interventions was high, the incidence of protocol violations was low and outcome data were available for
> 99% of the trial cohort. Event rates for the primary and secondary outcomes were similar to those that
were anticipated and as described in other cohort studies and RCTs involving very preterm infants.
The trial had sufficient power to detect important effects on the risk of late-onset infection and other
morbidities. More precise estimates of effect were able to be generated than were available previously.
The 95% CI for the relative risk estimate for the primary outcome excludes a > 14% risk reduction and
a ≥ 4% increase in risk. These estimates were consistent across gestational ages at birth and were not
affected by the type of enteral feeds that infants received during the trial period (human milk, formula or
both). It is therefore unlikely that lactoferrin has any important benefits for subgroups of infants at higher
risk of infection.
Estimates for the secondary outcomes indicated consistently that lactoferrin supplementation does not have
important effects on the risk of major morbidities. An analysis was prespecified of the effect on a composite
of infection, NEC, BPD, ROP and mortality. The adjusted RR point estimate for this secondary outcome
was 1.01, with a 99% CI excluding a > 6% reduction and a ≥ 8% increase in risk. As these morbidities,
particularly infection and NEC, are the major reasons for the receipt of invasive interventions and higher levels
of care in very preterm infants, it is not surprising that there were no effects shown on the level of exposure to
antimicrobial agents, or on the duration of hospitalisation or stay in intensive or high-dependency care settings.
SCIENTIFIC SUMMARY
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Given that the ELFIN trial did not show any differences between groups in the risk of morbidity or on levels
of care received, we do not plan to apply for permission and further funding to assess longer-term outcomes
of trial participants. Any between-group differences in growth and neurodevelopmental outcomes are
predicated largely on differences in the incidence of late-onset infections, NEC and associated morbidities.
As these differences were not shown, there is no longer an impelling rationale for expecting lactoferrin
supplementation to have an impact on long-term growth or development.
The ELFIN trial findings are applicable in the UK and internationally. Participants were enrolled in 37 neonatal
units across the country, providing broad geographical, and social and ethnic representation. Many infants
who were recruited were transferred subsequently to another neonatal unit, typically closer to the family
home, for ongoing care. Trial participation continued in these additional 97 neonatal units and this practice
mirrors managed clinical network care pathways for very preterm infants in the UK. The trial population was
representative of very preterm infants cared for within health-care facilities in well-resourced health services
and included a substantial proportion of extremely preterm infants (37%) and of infants with other putative
risk factors for neonatal morbidity, such as prolonged rupture of maternal amniotic membranes (25%) and
evidence of absent or reverse end diastolic flow in the fetal umbilical artery (12%). Overall, about 30% of
participants acquired a microbiologically confirmed or clinically suspected late-onset infection, and about
17% in total had a microbiologically confirmed infection, consistent with rates reported from cohort studies
and other RCTs. Similarly, the incidence of NEC (about 5%) was similar to rates reported in large,
population-based surveillance studies and RCTs.
Conclusion
These findings do not support the use of enteral bovine lactoferrin supplementation to prevent late-onset
infection or other morbidity in very preterm infants. Research efforts could continue to investigate the
aetiology, epidemiology and pathogenesis of late-onset infection and related morbidities, and to develop,
refine and assess other interventions that may prevent or reduce adverse acute and long-term consequences
for very preterm infants and their families.
Trial registration
This trial is registered as ISRCTN88261002.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. This trial was also sponsored by the University of Oxford, Oxford, UK. The
funder provided advice and support and monitored study progress but did not have a role in study design
or data collection, analysis and interpretation.
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Chapter 1 Introduction
Late-onset infection in very preterm infants
Late-onset invasive infection (occurring > 72 hours after birth) is the most common serious complication
associated with hospital care for preterm infants. The UK James Lind Alliance Preterm Birth Priority Setting
Partnership has identified the development and assessment of better methods to prevent infection in
preterm infants as a research priority.1
The incidence of late-onset infection is typically estimated to be > 20% in very preterm infants, reflecting the
level and duration of exposure to invasive procedures and intensive care.2,3 Very preterm infants who acquire a
late-onset bloodstream or deep-seated infection are at higher risk of mortality and a range of acute morbidities
including necrotising enterocolitis (NEC), retinopathy of prematurity (ROP) and bronchopulmonary dysplasia
(BPD) than comparable infants without infection.4–6 Over the long term, late-onset infection is associated with
higher rates of adverse neurodevelopmental outcomes, including visual, hearing and cognitive impairment, and
cerebral palsy.5
Mortality and morbidity are usually associated with Gram-negative bacterial, Staphylococcus aureus or fungal
bloodstream infections or meningitis.7–9 Coagulase-negative staphylococcal infection, despite accounting for
about half of all infections, is generally associated with a more benign clinical course.10 Meningitis and other
deep-seated infections are rare and the mortality rate is lower than that attributed to Gram-negative or other
Gram-positive bacterial infections. However, even low-grade coagulase-negative staphylococcal bloodstream
infections may generate inflammatory cascades that are associated with both acute morbidity (metabolic,
respiratory or thermal instability, thrombocytopenia) and long-term white matter and other brain damage
that may result in adverse neurodevelopmental outcomes.11
As a consequence of associated morbidities, very preterm infants with late-onset infection may spend about
20 more days in hospital than gestation-comparable infants without infection.12 Late-onset infection and
associated morbidities therefore have major consequences for perinatal health-care service management,
delivery and costs.
Diagnosis, treatment and prevention of late-onset invasive infection
Clinical signs and laboratory markers may be unreliable predictors of true late-onset infection, especially in
very preterm infants.13,14 A policy of early empirical treatment of suspected infection is usually implemented.
Most neonates who are treated as a result of ‘sepsis evaluation’, however, do not have infection confirmed
subsequently.15 This results in unnecessary exposure to antibiotics, which not only subjects very preterm
infants to more interventions but may drive the emergence of antibiotic-resistant pathogens in the neonatal
unit.16,17 Although generic infection control measures, such as hand-washing and intravascular catheter
‘care bundles’, have helped to prevent some episodes of late-onset invasive infection in very preterm infants,
benchmarking and quality improvement studies in neonatal networks have indicated that there is a need for
measures to further reduce the incidence.18
Given this burden of mortality, acute and long-term morbidity, and costs to families and health services,
there is a need to develop innovative strategies to prevent late-onset invasive infection in very preterm
infants.19
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Lactoferrin
Lactoferrin, a member of the transferrin family of iron-binding glycoproteins, is a key component of the
mammalian innate response to infection.20–22 It is the major whey protein in human colostrum, present at a
concentration of about 6 mg/ml and is present in mature breast milk at a concentration of about 1 mg/ml.23
Lactoferrin is also present in mammalian tears, saliva, cerebrospinal fluid (CSF) and other secretions.22
Lactoferrin has broad microbiocidal activity by mechanisms, such as cell membrane disruption, iron
sequestration, the inhibition of microbial adhesion to host cells and the prevention of biofilm formation
(Box 1).20,21 Development of resistance to lactoferrin is improbable as it would require multiple simultaneous
mutations. Lactoferrin remains a potent inhibitor of viruses, bacteria, fungi and protozoa after millions of
years of mammalian evolution.24,25
Lactoferrin has prebiotic properties, creating an enteric environment that promotes the growth of beneficial
bacteria and reducing colonisation with pathogenic species.26,27 It has direct intestinal immunomodulatory
and anti-inflammatory actions mediated by modulating cytokine expression, mobilising leucocytes into the
circulation and activating T-lymphocytes.28,29 At high concentrations, as in colostrum, lactoferrin enhances
the proliferation of enterocytes and the closure of enteric gap junctions.30 At lower concentrations,
lactoferrin stimulates the differentiation of enterocytes and the expression of intestinal digestive enzymes.31
Lactoferrin suppresses free-radical activity when iron is added to milk, suggesting that it may have further
anti-inflammatory actions that could modulate the pathogenesis of diseases linked with free-radical
generation, such as NEC, ROP and BPD.32
Bovine lactoferrin
Bovine lactoferrin (The Tatua Cooperative Dairy Company Ltd, Morrinsville, New Zealand) is > 70%
homologous with human lactoferrin but has higher antimicrobial activity. It is inexpensive compared with
BOX 1 Lactoferrin: mechanisms of action
l Antimicrobial effects:
¢ cell membrane disruption
¢ iron sequestration
¢ inhibition of microbial adhesion to host cells
¢ prevention of biofilm formation.
l Prebiotic effects:
¢ promote intestinal growth of beneficial bacteria (probiotics)
¢ reduce colonisation with pathogenic species.
l Immune-modulatory and anti-inflammatory actions:
¢ modulate cytokine expression
¢ mobilise leucocytes into the circulation
¢ activate T-lymphocytes
¢ suppress free-radical activity.
l Intestinal integrity effects:
¢ stimulate differentiation and proliferation of enterocytes
¢ promote closure of enteric gap junctions
¢ increase expression of intestinal digestive enzymes.
INTRODUCTION
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human or recombinant lactoferrin and is available commercially as a food supplement in a stable powder
form.33 The affinity of bovine lactoferrin for the human small intestine lactoferrin receptor is low and intact
lactoferrin and digested fragments (lactoferricins), which also have high microbiocidal activity, are excreted
enterally.34,35 Bovine lactoferrin has been a component of the human infant diet for thousands of years and
is registered as ‘Generally Recognised As Safe’ by the US Federal Drug Administration with no reports of
human toxicity.36 The ‘no observed adverse effect level’ is > 2 g/kg/day in rodents.37 Given the absence of
adverse effects, the European Food Safety Authority Panel concluded that bovine lactoferrin for infants
is safe at the standard supplementation levels (up to about 210 mg/kg of body weight per day).38
Lactoferrin supplementation
Very preterm infants typically ingest little or no milk during the early neonatal period and thus have low
lactoferrin intake. This deficiency may be further exacerbated by delays in establishing enteral feeding.
Enteral lactoferrin supplementation has been proposed and assessed as a simple strategy to compensate
for this gestational immunodeficiency.39
Existing evidence
The Cochrane review by Pammi and Suresh40 identified six completed randomised controlled trials (RCTs),
involving 1071 participants in total.41–46 Meta-analyses suggest that enteral supplementation with lactoferrin
reduces the incidence of late-onset invasive infection by about 40%; the effect size is similar whether
infants are fed predominantly human milk or formula milk. The incidence of NEC is decreased by about
60%. No evidence of an effect on all-cause mortality was found and no adverse effects or intolerance were
reported (Box 2). However, because the trials were generally small and contained various methodological
weaknesses that increased the risk of selection and performance bias, and because meta-analyses were
limited by data availability and heterogeneity, the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) working group assessment of the quality of this evidence was ‘low’, meaning that
further research was likely to have an important impact on the confidence in the estimates of effect and is
likely to change these estimates. The Cochrane review concluded that additional data from large, good-quality
RCTs of lactoferrin supplementation in very preterm infants were needed to enhance the validity and
applicability of the evidence-base sufficiently to inform policy and practice.40
Objective
The study aimed to assess the effect of enteral administration of bovine lactoferrin on the incidence of
late-onset infection, other morbidity and mortality in very preterm infants.
BOX 2 Summary findings of the Cochrane review meta-analyses40
l Late-onset infection: typical RR 0.59, 95% CI 0.40 to 0.87; typical RD –0.06, 95% CI –0.10 to –0.02;
number needed to treat for an additional beneficial outcome was 17, 95% CI 10 to 50; six trials,
886 participants.
l Necrotising enterocolitis (Bell’s stage II or III): typical RR 0.40, 95% CI 0.18 to 0.86; typical RD –0.04, 95% CI
–0.06 to –0.01; number needed to treat for an additional beneficial outcome was 25, 95% CI 17 to 100;
four trials, 750 participants.
l All-cause mortality: typical RR 0.65, 95% CI 0.37 to 1.11; typical RD –0.02, 95% CI –0.05 to 0; six trials,
1071 participants.
CI, confidence interval; RD, risk difference; RR, risk ratio.
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Chapter 2 Methods
Design
The Enteral Lactoferrin In Neonates (ELFIN) trial was a UK, multicentre, parallel-group, placebo-controlled
RCT (see www.npeu.ox.ac.uk/elfin).47
Ethics approval and research governance
The ELFIN trial protocol was approved by the National Research Ethics Service Committee East Midlands –
Nottingham 2 on 2 April 2013 (reference number 13/EM/0118).
Local approval and site-specific assessments were obtained from the NHS trusts for trial sites.
The trial was registered with the International Standard Randomised Controlled Trial Register
(https://doi.org/10.1186/ISRCTN88261002).
Patient and public involvement
During the development and delivery of the ELFIN trial, we engaged with infant and family representatives
experienced in voicing service users’ views (principally via Bliss, a UK national charity supporting preterm or
sick newborn infants and their families: www.bliss.org.uk/). Parents with children who had received neonatal
intensive care contributed via Bliss and directly to the development of trial materials (e.g. parent information
and resources) and research staff training (e.g. in simulated sessions on ‘seeking consent’). We adhered
to INVOLVE good practice guidelines to ensure service-user leadership in the delivery of the trial and
dissemination of the findings (www.invo.org.uk/).
Participants
Inclusion criteria
l Gestational age at birth of < 32 weeks.
l < 72 hours old at randomisation.
l Written informed parental consent.
Exclusion criteria
l Severe congenital anomaly.
l Anticipated enteral fasting for > 14 days.
l No realistic prospect of survival.
Infants receiving antibiotic treatment at randomisation were eligible to participate.
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Setting
Neonatal units in the UK caring for very preterm infants:
l recruiting sites where parents’ consent was obtained and infants could be recruited and randomised to
commence participation in the trial (n = 37; see Appendix 1)
l continuing care sites where clinicians continued to administer the intervention and collect routine data
if a participating infant of < 34 weeks’ postmenstrual age was transferred from a recruiting site
(n = 97; see Appendix 2).
Depending on the interventions being given, it was possible for an infant to participate in other clinical trials at
the same time as participating in the ELFIN trial. The Speed of Increasing Milk Feeds Trial (SIFT) was designed
to allow infants to be enrolled in both trials.48 The ELFIN trial and SIFT shared procedures and, in some cases,
joint data collection forms and other documentation. Other trials being run simultaneously in any units were
discussed by the chief investigators or their delegated representative to agree whether or not joint recruitment
was appropriate and likely to be acceptable.
Screening and eligibility assessment
Potential participants meeting the eligibility criteria were identified by the local health-care team. As the
eligibility criteria did not require specific medical assessment, assessment of eligibility was accepted to be
within the scope of competency of appropriately trained and experienced neonatal nurses, if so delegated
by the principal investigator (PI).
Informed consent and recruitment
Consent was sought from parents of potential participants only after they had received a full verbal
and written explanation of the trial [parent information leaflet (PIL); see www.npeu.ox.ac.uk/elfin/
parent-resources (accessed 29 June 2018)]. Parents who did not speak English were approached only
if an adult interpreter was available.
Informing potential participants’ parents of possible benefits and risks occurred as a staged process.49
If it was likely that the expected infant was eligible to participate in the trial, the PIL and preliminary verbal
information was offered prior to birth. Further verbal information was provided after birth as it was to the
parents of infants who were not identified antenatally.
Written informed parental consent was obtained by means of dated parental signature and the signature
of the person who obtained informed consent: the PI or health-care professional with delegated authority
(see www.npeu.ox.ac.uk/elfin/neonatal-staff). A copy of the signed informed consent form was given
to the parents. A copy was retained in the infant’s medical notes, a copy was retained by the PI and the
original was sent to the Clinical Trials Unit.
Participants or parents were not given any financial or material incentive or compensation to take part. It
was made clear that parents remained free to withdraw their infant from the trial at any time without the
need to provide any reason or explanation. Parents were aware that this decision would have no impact
on any aspects of their infant’s continuing care.
The trial entry form was completed after informed consent had been given. The recorded information
was entered on to the National Perinatal Epidemiology Unit Clinical Trials Unit (NPEU CTU) randomisation
website [see https://rct.npeu.ox.ac.uk/ (accessed 29 June 2018)]. Infants were considered to have been
enrolled once they have been given a study number and have been allocated a treatment pack number by
the randomisation facility.
METHODS
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Intervention
Trial participants were allocated randomly to receive either:
l bovine lactoferrin or
l sucrose (British Sugar, Peterborough, UK).
The UK Medicines and Healthcare Regulatory Agency (MHRA) indicated that, for the purposes of the trial,
the intervention and sucrose placebo were considered to be Investigational Medicinal Products (IMPs)
and subject to good manufacturing practice (GMP) regulations. After discussion with MHRA, the IMP
was considered to be ‘category B’ (risk slightly above routine practice because bovine lactoferrin is not a
licensed product).
Bulk lactoferrin was imported from The Tatua Cooperative Dairy Company Ltd, a New Zealand-based
company that manufactures highly purified powder (see www.tatua.com/specialty-nutritionals-ingredients/
lactoferrin/).
Bulk sucrose was obtained in the UK from British Sugar (see www.britishsugar.co.uk/).
The IMP was packaged into individual doses in sealed opaque containers and assembled into participant
packs to GMP in the MHRA-approved NHS clinical trials pharmacy unit at the Royal Victoria Hospital,
Newcastle upon Tyne (www.newcastle-hospitals.org.uk/services/Pharmacy_services_newcastle-specials-
pharmacy-production-unit.aspx).
Investigational Medicinal Product management
l Bovine lactoferrin was packaged into 25-ml opaque pharmacy pots (fill equivalent to 375 mg per pot)
at the trials pharmacy in Newcastle Royal Infirmary, Newcastle upon Tyne, UK. Boxes containing 24
identically numbered pots were labelled with the same pack identification (ID) number to indicate that
they all belonged to the same treatment course. At randomisation, infants were allocated a study
number and a pack ID number; the study number was added to the label of the allocated pack with
the infant’s name and date of birth for checking before each administration of the IMP. Lactoferrin
powder was stable within unopened pots and could be stored at room temperature. When the infant
completed the course of treatment, any unused IMP pots were retained for accounting and destruction
by the site pharmacist.
l Sucrose was processed, packaged and distributed as for bovine lactoferrin.
Investigational Medicinal Product prescription and preparation
Lactoferrin and sucrose were prescribed at a dose of 150 mg/kg body weight per day (up to a maximum of
300 mg/day). The IMP was prepared by neonatal nurses or clinicians on the neonatal unit in the unit milk
kitchen or other appropriate area determined locally. The IMP powder was prepared for administration by
mixing in sterile water plus expressed breast or formula (see Appendix 3).
The IMP was administered once daily by nasogastric or orogastric tube or orally once the enteral feed
volume was > 12 ml/kg/day and continued until 34 weeks’ postmenstrual age. Some small infants may
have had the dose split at the discretion of the responsible clinical team. A maximum of 70 days of
treatment was given.
All other aspects of care, including the timing of the commencement of enteral feeds and the type of milk
feed used, were as per local policy, practice and discretion.
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Randomisation
Randomisation of participants to receive either lactoferrin or sucrose was managed via a secure web-based
randomisation facility hosted by the NPEU CTU, University of Oxford, Oxford, UK. Telephone assistance
and randomisation back-up was available at all times.
To confirm eligibility, investigators needed to supply gestational age, sex and time of birth. To proceed to
randomisation, investigators needed to confirm that signed informed consent was available. Infants were
allocated to the lactoferrin versus sucrose groups in the ratio of 1 : 1 using a minimisation algorithm to
ensure balance between the groups with respect to the recruiting site (neonatal unit), sex, single versus
multiple births and gestational age in completed weeks. Twins or higher order multiple births were
randomised individually.
Allocation concealment and blinding
Participating infants were randomly allocated a numbered pack containing either the lactoferrin or the
placebo and allocated a unique study number. Parents, clinicians, investigators and outcomes assessors
were unaware of the allocated treatment groups.
Stopping Investigational Medicinal Product
Administration of the trial IMP may have been stopped temporarily. Missed doses did not necessitate the
removal of an infant from the trial. Data continued to be collected as per protocol if the trial medication
was stopped temporarily or permanently in order to facilitate an unbiased treatment comparison via an
intention-to-treat analysis.
Masking
Bovine lactoferrin has a pale pink/brown tinge, whereas sucrose was very light brown. The opaque containers
did not allow the dry IMP to be seen unless the sealed stopper was removed intentionally. The lactoferrin
powder had similar granularity to sucrose so that when the dry IMP was shaken within the opaque, sealed
pots it was not possible to distinguish lactoferrin from sucrose by the sound generated. Mixing the IMP
with sterile water plus breast milk or formula generated foam that settled within 30 minutes after shaking.
When the mixed IMP was removed in a syringe with a purple plunger, the pink tinge to the lactoferrin was
disguised by the colour of the breast milk or formula, which often resulted in a light brown colour (and this
varied markedly between batches of milk). As lactoferrin was more likely than sucrose to retain a light pink
tinge, all sites were supplied with a laminated picture of a range of possible colours for the IMP mixture in
syringes, and it was stressed that this applied to both lactoferrin and sucrose.
Clinicians were able to request knowledge of the treatment allocation to guide the clinical management of
the participant if it was deemed to be an emergency situation. In such instances, a single-use access code
was provided in a sealed envelope and the participant’s allocation was unmasked via the randomisation
website.
Internal pilot
An internal pilot study was conducted in six neonatal centres within the Northern Region and Yorkshire
Neonatal Networks (‘operational delivery networks’) to test whether or not the components and processes
of the study worked together and ran smoothly. The main aims of the pilot were to:
1. confirm that regulatory processes were in order
2. ensure that the randomisation process was acceptable and effective
3. demonstrate efficient intervention and placebo preparation and distribution
4. determine that the anticipated acceptance rate (40% of eligible infants) was achievable
METHODS
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5. determine whether or not the projected recruitment rate was realistic – we set a target of a total of
4, 6 and 8 infants recruited in months 1, 2 and 3, respectively, expecting to reach a ‘steady state’ of a
total of 10 infants (two per month per centre) by month 4 of the pilot phase
6. evaluate the delivery, management and acceptability (to families and staff) and ease of preparation
and administration
7. assess the processes for collecting clinical outcomes and event rates and to determine that the
predicted retention rate (> 95% of recruited infants) was attainable.
The decision to progress with the main trial was made in consultation with the Trial Steering Committee
(TSC) and the funder.
The internal pilot phase was followed by a 3-year main recruitment phase in 37 recruiting centres
(see Appendix 1).
Outcomes
Primary outcome
The number of infants who experience at least one episode of microbiologically confirmed (Box 3) or
clinically suspected (Box 4) late-onset infection from trial entry until hospital discharge.
Secondary outcomes
l Microbiologically confirmed infection (see Box 3).
l All-cause mortality prior to hospital discharge.
l Necrotising enterocolitis: Bell’s stage II or III (see Appendix 4).52
l Severe ROP treated medically or surgically.53
l Bronchopulmonary dysplasia: when the infant is still receiving mechanical ventilator support or
supplemental oxygen at 36 weeks’ postmenstrual age.54
l A composite of invasive infection, major morbidity (NEC, ROP or BPD) and mortality.
l Total number of days of administration of antimicrobials per infant from trial entry until 34 weeks’
postmenstrual age.
l Total length of stay until discharge home.
l Length of stay in (1) intensive care, (2) high-dependency and (3) special-care settings (see Appendix 5).
BOX 3 Definition of microbiologically confirmed late-onset infection
Microbiological culture from blood or CSF sampled aseptically > 72 hours after birth of any of the following:
l potentially pathogenic bacteria (including coagulase-negative Staphylococcus species but excluding
probable skin contaminants, such as diphtheroids, micrococci, propionibacteria or a mixed flora)
l fungi.
AND treatment, or clinician intention to treat, for ≥ 5 days with intravenous antibiotics (excluding antimicrobial
prophylaxis) after investigation was undertaken. If the infant died or was discharged or transferred prior to the
completion of 5 days of antibiotics this condition would still be met if the intention was to treat for ≥ 5 days.
Adapted from the UK Neonatal Infection Surveillance Network case definition.2,3
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Sample size
The sample size estimate was informed by a range of plausible primary outcome control event rates (CERs)
from 18% to 24%, based on surveillance reports from Europe, North America and Australasia (Table 1).2,7,8,10,12
In summary, with 90% power and a two-sided 5% significance level, to detect an absolute risk reduction
(ARR) of 5–5.8% (relative risk reduction of between 24% and 28%) would require a total of up to 2200
participants if the CER was 18%, 2070 if the CER was 21% and 2076 if the CER was 24%. This target sample
size of 2200 allowed for an anticipated loss to follow-up of up to 5%. This sample size was sufficient to
exclude important effects on secondary outcomes with 90% power [e.g. a 7% ARR in antibiotic exposure
(from 45% to 38%)].
The participating recruiting neonatal units were estimated to admit 60 very preterm infants per annum on
average. Based on 40% recruitment, 30 units were estimated to be able to recruit a total sample size of
up to 2160 infants over 3 years (an average of two infants per unit per month).
BOX 4 Definition of clinically suspected late-onset infection
Absence of positive microbiological culture, or culture of a mixed microbial flora or of likely skin contaminants
(diphtheroids, micrococci, propionibacteria) only
AND treatment, or clinician intention to treat, for ≥ 5 days with intravenous antibiotics (excluding antimicrobial
prophylaxis) after the above investigation was undertaken for an infant who demonstrates three or more of the
following clinical or laboratory features of invasive infection:
l increase in oxygen requirement or ventilatory support
l increase in frequency of episodes of bradycardia or apnoea
l temperature instability
l ileus or enteral feeds intolerance or abdominal distension
l reduced urine output to < 1ml/kg/hour
l impaired peripheral perfusion (capillary refill time of > 3 seconds, skin mottling or core–peripheral
temperature gap > 2 °C)
l hypotension (clinician defined as needing volume or inotrope support)
l ‘irritability or lethargy or hypotonia’ (clinician defined)
l increase in serum C-reactive protein levels to > 15mg/l or procalcitonin level of ≥ 2 ng/ml
l white blood cells count of < 4 × 109/l or > 20 × 109/l
l cells/l or platelet count of < 100 × 109/l
l glucose intolerance (blood glucose levels of < 40mg/dl or > 180 mg/dl)
l metabolic acidosis (base excess of < –10mmol/l or lactate level of > 2mmol/l).
Adapted from the European Medicines Agency consensus criteria and predictive model.50,51
TABLE 1 Participants required per arm by CER
Control event
rate (%)
Treatment group
event rate (%)
Absolute risk
reduction (%)
Relative risk
reduction (%)
Number
required
per arm
Total sample
size required
24 18.2 5.8 24 1038 2076
21 15.5 5.5 26 1035 2070
18 13.0 5.0 28 1099 2200
METHODS
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Statistical analyses
Demographic factors and clinical characteristics at randomisation were summarised with counts (percentages)
for categorical variables, mean [standard deviation (SD)] for normally distributed continuous variables or
median [interquartile range (IQR)] for other continuous variables.
Outcomes for participants were analysed in the groups to which they were assigned regardless of deviation
from the protocol or treatment received. Comparative analyses calculated the relative risk ratio (RR) with 95%
confidence interval (CI) for the primary outcome (99% CIs for all other dichotomous outcomes), the mean
difference (99% CI) for normally distributed continuous outcomes or the median difference (99% CI) for
skewed continuous variables.
The groups were compared using regression analysis adjusting for the minimisation factors (recruiting
centre, sex, weeks’ gestation at birth and single vs. multiple births) to account for the correlation between
treatment groups introduced by balancing the randomisation. We used random-effects models with centre
fitted as a random effect and mother’s ID number nested within this to take account of clustering within
centre and within multiples. The other minimisation factors were fitted as fixed effects, with sex and
multiplicity of birth included as binary variables and gestational age modelled as a continuous variable.
The crude unadjusted and adjusted estimates were calculated with the primary inference to be based on
the adjusted analysis.
The consistency of the effect of lactoferrin supplementation on the primary outcome across specific
subgroups of infants was assessed using the statistical test of interaction. Prespecified subgroups were
(1) completed weeks of gestation at birth and (2) infants given maternal or donated expressed breast milk
versus formula versus both human milk and formula during the trial period (received on > 50% of days
on which infant is fed enterally until developing late-onset infection or NEC, dying or reaching 34 weeks’
postmenstrual age).
Data collection
All of the outcome data for this trial were routinely recorded clinical items that could be obtained from the
clinical notes or local microbiology laboratory records. Information was collected using the data collection
forms (see Appendix 6).
A ‘blinded end-point review committee’, masked to participant allocation, reviewed all case report forms
(CRFs) reporting episodes of late-onset infection or necrotising enterocolitis or other gastrointestinal pathology.
Two members independently assessed adherence to case definitions and resolved any disagreements or
discrepancies by discussion or referral to a third committee member or both. Persisting uncertainties were
discussed with the site PI or research nurse or both until resolved.
Adverse event reporting
Some adverse events were foreseeable (expected) because of the nature of the participant population,
and their routine care and treatment. No adverse drug reactions were expected from bovine lactoferrin.
Consequently, only those adverse events (or reactions) identified as serious were recorded for this trial
(see Appendix 7).
Expected serious adverse events (SAEs) were recorded on the CRFs. All other SAEs were reported by trial
sites to the NPEU CTU within 24 hours of the event being recognised. Information was recorded on a
SAE reporting form and faxed to the NPEU CTU. Additional information (follow-up of or corrections to the
original case) needed to be detailed on a new SAE form and faxed to the NPEU CTU. A standard operating
procedure (SOP) outlining the reporting procedure for clinicians was provided with the SAE form and in
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the trial handbook. The NPEU CTU processed and reported the event as specified in its own SOPs. All SAEs
were reviewed by the Data Monitoring Committee (DMC) at regular intervals throughout the trial. The CI
informed all investigators of information that could affect the safety of participants.
Suspected unexpected serious adverse reactions
Suspected unexpected serious adverse reactions (SUSARs) were reported to the MHRA and the approving
Research Ethics Committee (REC) within 7 days, if life-threatening, and within 15 days for other SUSARs.
In addition, a copy of the SUSAR form was forwarded to the chairperson of the DMC. The chairperson
was provided with details of all previous SUSARs with their unmasked allocation. The chief investigator
informed all investigators of any issues raised in a SUSAR that could affect the safety of participants.
Development safety update report
In addition to the expedited reporting above, the chief investigator submitted, once a year throughout the
clinical trial, or on request, a development safety update report to the Competent Authority, the Ethics
Committee and the sponsor.
Economic analysis (planned)
We planned to combine the health service resources used during an infant’s hospital admission with
clinical effectiveness data to conduct an economic evaluation to assess whether or not the intervention
was likely to be cost-effective over the time horizon of the trial period. If appropriate, we intended to
synthesise the costs and consequences of the intervention to generate an incremental cost-effectiveness
ratio to inform any adoption decision. We planned to use regression models to allow for differences in
prognostic variables, principally gestational age bands, and other sources of heterogeneity and to assess
differences in the probable cost-effectiveness between the groups.
The primary outcome for an economic analysis was the incidence of late-onset invasive infection. As invasive
infection is linked closely to morbidity and mortality, it is likely that the consequences will continue to appear
over a longer time frame and may have an impact on both duration and quality of life. Therefore, as a second
analysis, we intended to develop an economic model to account for projected longer-term costs and effects
and to estimate the additional cost per quality-adjusted life-year gained of lactoferrin compared with placebo.
Governance and monitoring
At least one site initiation visit was conducted at all recruiting sites. The trial research nurse and the chief
investigator or a delegated co-investigator provided structured training for site investigators, local research
nurses and other clinical staff, including the site pharmacy team responsible for IMP management. Training
focused on approaches to consent, protocol processes and governance requirements. These visits were
supported with bespoke written and online training material available to all staff via the trial website
(www.npeu.ox.ac.uk/elfin/training). Staff in continuing care sites did not have initiation visits unless requested
but were directed to online training and access support from the chief investigator and trial research nurse
as needed.
Ongoing monitoring included review of investigator site files, delegation logs, staff qualifications and
training (good clinical practice certificates, curricula vitae) and pharmacy documentation. Quality assurance
was achieved by following data management procedures at the study data centre and data monitoring at
trial sites. Further site monitoring or audit was conducted if central monitoring exercises raised concern
about patterns of recruitment or data reporting. This monitoring approach was justified by the level of risk
associated with the trial and the intervention.
METHODS
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Data management was undertaken in accordance with NPEU CTU SOPs and a prespecified management
plan. Data monitoring included the review of consent forms and participant eligibility. Additional data
validation checks were carried out periodically, with data queries issued to study sites for resolution. Prior
to database lock, final data validation checks were carried out and questions were resolved by discussion
with the site PI or local research nurse, when possible.
During the trial, the study statisticians produced reports for the TSC and independent DMC. Issues of data
quality identified by study statisticians were reported to study data management staff and queried when
appropriate or included in future routing data validation checks, or both. TSC and DMC meetings provided
opportunities for the external, independent review of summary data, with additional feedback on potential
data quality issues being incorporated into ongoing data quality checks.
Summary of changes to the study protocol
A summary of the changes made to the original protocol is presented in Appendix 8.
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Chapter 3 Results
Recruitment and retention
Recruitment and retention to the trial are summarised in the flow chart (Figure 1).
The internal pilot was undertaken in six neonatal units between May 2014 and April 2015. In total,
90 infants were recruited to participate. The main trial recruited infants from 37 neonatal units (including
the six pilot sites) from July 2015 to September 2017 (when the recruitment target was reached). The trial
randomised 2203 infants in total:
l 1099 infants were allocated to receive bovine lactoferrin
l 1104 infants were allocated to receive the sucrose placebo.
Four infants had consent withdrawn or unconfirmed. In total, 1098 infants in the lactoferrin group and
1101 in the placebo group were included in the intention-to-treat analyses (see Appendix 9).
Demographic and other baseline characteristics
The baseline characteristics and other demographic features of participating infants were well balanced
between the two treatment allocation groups (Table 2). The median gestation age was 29 weeks in both
groups (37% aged < 28 weeks). The median birthweight was 1126 g in the lactoferrin group and 1143 g
in the placebo group. Overall, 91% of infants were exposed to antenatal corticosteroid, 57% were born
via caesarean section, 25% were born following rupture of maternal amniotic membranes for > 24 hours,
Infants randomised
(n = 2203)
(1863 women)
Infants allocated to lactoferrin
(n = 1099)
• Received no doses, n = 21 (1.9%)
• Randomised in error, n = 8 (0.7%)
   • Randomised at > 72 hours, n = 7
   • Consent not confirmed, n = 1
• Withdrawn, n = 20 (1.8%)
• Consent to use data remains,a n = 20
Babies included in analysis of
outcomes at discharge
(n = 1098) 
• Consent not confirmed, n = 1
• Outcome status not known,b n = 21
Babies included in analysis of
outcomes at discharge
(n = 1101)
• Withdrawn consent to use data, n = 3
• Outcome status not known,b n = 24
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Infants allocated to placebo
(n = 1104)
• Received no doses, n = 31 (2.8%)
• Received ≥ 1 dose of lactoferrin, n = 1
• Randomised in error, n = 1 (0.1%)
   • Randomised at > 72 hours, n = 1
• Withdrawn, n = 15 (1.4%)
• Withdrawn consent to use data, n = 3
• Consent to use data remains,a n = 12
FIGURE 1 Flow of participants through the trial. a, Included in the analysis when data are available; b, included in
analysis except when knowledge of discharge or discharge date is required.
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TABLE 2 Infant and maternal characteristics at randomisation
Characteristic
Trial group
Lactoferrin (n= 1098) Placebo (n= 1101)
Number of centres, n 37 37
Male sex, n/N (%) 575/1098 (52.4) 578/1099 (52.6)
Missing, n 0 2
Infant age at randomisation in days
Median (IQR) 2 (2–3) 2 (2–3)
Birthweight (g)
Mean (SD) 1125.9 (356.2) 1143.3 (367.1)
< 500, n (%) 8/1098 (0.7) 7/1101 (0.6)
500 to 749, n (%) 172/1098 (15.7) 172/1101 (15.6)
750 to 999, n (%) 254/1098 (23.1) 244/1101 (22.2)
1000 to 1249, n (%) 268/1098 (24.4) 255/1101 (23.2)
1250 to 1499, n (%) 199/1098 (18.1) 199/1101 (18.1)
≥ 1500, n (%) 197/1098 (17.9) 224/1101 (20.3)
Birthweight < 10th centile for gestational age, n/N (%) 175/1097 (16.0) 177/1098 (16.1)
Missing, n 1 3
Gestation at delivery (completed weeks)
Median (IQR) 29 (27–30) 29 (27–30)
< 23, n/N (%) 1/1098 (0.1) 1/1101 (0.1)
23+0 to 23+6, n/N (%) 33/1098 (3.0) 31/1101 (2.8)
24+0 to 24+6, n/N (%) 73/1098 (6.6) 76/1101 (6.9)
25+0 to 25+6, n/N (%) 73/1098 (6.6) 73/1101 (6.6)
26+0 to 27+6, n/N (%) 227/1098 (20.7) 221/1101 (20.1)
28+0 to 29+6, n/N (%) 315/1098 (28.7) 319/1101 (29.0)
30+0 to 31+6, n/N (%) 376/1098 (34.2) 380/1101 (34.5)
Mother’s age at randomisation (years)
Mean (SD) 30.3 (6.1) 30.4 (6.0)
Multiple birth, n/N (%) 350/1098 (31.9) 346/1101 (31.4)
Caesarean section delivery, n/N (%) 635/1098 (57.8) 616/1101 (55.9)
Membranes ruptured before labour, n/N (%) 422/1093 (38.6) 428/1097 (39.0)
Missing, n 5 4
Membranes ruptured > 24 hours before delivery, n/N (%) 286/1092 (26.2) 264/1096 (24.1)
Missing, n 6 5
Mother received antenatal corticosteroids, n/N (%) 998/1093 (91.3) 997/1099 (90.7)
Missing, n 5 2
Infant heart rate of > 100 b.p.m. at 5 minutes, n/N (%) 995/1090 (91.3) 1010/1093 (92.4)
Missing, n 8 8
RESULTS
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and 12% had evidence of absent or reverse end diastolic flow in the fetal umbilical artery. The allocation
arms were well-balanced in individual recruiting sites as per the minimisation algorithm (see Appendix 10).
Adherence
A total of 35 (1.6%) infants discontinued the intervention early: 20 in the lactoferrin group and 15 in the
sucrose group. This includes a small number of infants who in the early stages of the trial discontinued
the intervention because they were transferred to a hospital that did not have the regulatory approvals to
administer the intervention. Parental consent remained for data collection for intention-to-treat analyses
for 32 out of the 35 infants.
Adherence was high for infants who continued to receive the IMP (Table 3). The median percentage of
days when an IMP dose was not given or not recorded was 4% in both treatment groups, and 0% of
days in both groups for the dose not given or not recorded when those days where feeds were stopped
or withheld for > 4 hours (for clinical reasons) were excluded. The median difference between expected
dose and actual dose per day was 7 mg/kg/day lower in both groups and was 1 mg/kg/day (lactoferrin)
or 2 mg/kg/day (sucrose) lower excluding those days where enteral feeds were stopped or withheld for
> 4 hours.
Outcomes
The estimates of effect for the primary and secondary outcomes are presented in Table 4.
Primary outcome
Data were available for 2182 infants (99%). In the lactoferrin group, 316 out of 1093 (28.9%) infants
acquired a late-onset infection versus 334 out of 1089 (30.7%) infants in the control (placebo) group
(adjusted RR 0.95, 95% CI 0.81 to 1.10).
TABLE 2 Infant and maternal characteristics at randomisation (continued )
Characteristic
Trial group
Lactoferrin (n= 1098) Placebo (n= 1101)
Infant temperature on admission (°C)
Mean (SD) 36.9 (0.7) 37 (0.7)
Missing, n 4 10
Infant worst base excess within first 24 hours of birth
Mean (SD) –6.2 (3.9) –6.3 (3.8)
Missing, n 9 12
Infant ventilated via endotracheal tube at randomisation, n/N (%) 338/1098 (30.8) 357/1101 (32.4)
Infant had absent or reverse end diastolic flow, n/N (%) 134/1079 (12.4) 130/1081 (12.0)
Missing, n 19 20
b.p.m., beats per minute.
Bold indicates minimisation factors.
Unless otherwise stated, the table gives the percentages of babies with data in that arm of the trial who had (or whose
mother had) the stated characteristic.
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TABLE 3 Adherences measures
Measure
Trial group
Lactoferrin (n= 1007)a Placebo (n= 1011)a
Percentage of days dose not given or not recordedb
Median (IQR) 4 (0 to 18.18) 4 (0 to 16.22)
Range 0 to 100 0 to 100
Missing, n 10 13
Percentage of days dose not given or not recorded, excluding days
where feeds were stopped or withheld for > 4 hoursb
Median (IQR) 0 (0 to 5.71) 0 (0 to 5.56)
Range 0 to 100 0 to 100
Missing, n 11 13
Difference between expected dose and actual dose per day (mg/kg/day)c
Median (IQR) –7 (–29 to 0) –7 (–27 to 0)
Range –150 to 253 –150 to 88
Missing, n 10 13
Difference between expected dose and actual dose per day, excluding
days where feeds were stopped or withheld for > 4 hours (mg/kg/day)c
Median (IQR) –1 (–11 to 0) –2 (–11 to 0)
Range –150 to 271 –150 to 88
Missing, n 11 13
a Includes only infants who have completed at least one feed log, and doses are exclusively recorded on version 2 of the
daily dosing log.
b The ratio of the number of days the dose was not given or recorded over the number of days in the expected
treatment window.
c The average difference between the expected dose and actual dose over every day of treatment window. When
necessary, the working weight is imputed using last observation carried forward.
TABLE 4 Primary and secondary outcomes
Outcome
Trial group
Unadjusted
RR (CI)a,b
Adjusted
RR (CI)a,b,c p-valued
Lactoferrin
(n= 1098)
Placebo
(n= 1101)
Microbiologically confirmed or clinically
suspected late-onset infection, n/N (%)
316/1093
(28.9)
334/1089
(30.7)
0.94
(0.83 to 1.07)
0.95
(0.86 to 1.04)
0.233
Missing, n 5 12
Microbiologically confirmed late-onset
infection, n/N (%)
190/1093
(17.4)
180/1089
(16.5)
1.05
(0.82 to 1.34)
1.05
(0.87 to 1.26)
0.490
Missing, n 5 12
All-cause mortality, n/N (%) 71/1076
(6.6)
68/1076
(6.3)
1.04
(0.69 to 1.59)
1.05
(0.66 to 1.68)
0.782
Missing, n 22 25
NEC (Bell’s stage II or III), n/N (%) 63/1085
(5.8)
56/1084
(5.2)
1.12
(0.71 to 1.77)
1.13
(0.68 to 1.89)
0.538
Missing, n 13 17
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TABLE 4 Primary and secondary outcomes (continued )
Outcome
Trial group
Unadjusted
RR (CI)a,b
Adjusted
RR (CI)a,b,c p-valued
Lactoferrin
(n= 1098)
Placebo
(n= 1101)
Severe ROP treated medically or
surgically, n/N (%)
64/1080
(5.9)
72/1080
(6.7)
0.89
(0.58 to 1.35)
0.89
(0.62 to 1.28)
0.420
Missing, n 18 21
BPD at 36 weeks’ postmenstrual age,
n/N (%)
358/1023
(35.0)
355/1027
(34.6)
1.01
(0.87 to 1.18)
1.01
(0.90 to 1.13)
0.867
Died before 36 weeks’
postmenstrual age
64 60
Missing, n 11 14
Infection, NEC, ROP, BPD or mortality,
n/N (%)
525/1092
(48.1)
521/1094
(47.6)
1.01
(0.90 to 1.13)
1.01
(0.94 to 1.08)
0.743
Missing, n 6 7
Total number of days of administration
of antimicrobials from commencement
of IMP until 34 weeks’ postmenstrual
age
Median (IQR) 2 (0–8) 3 (0–8) 0 (0 to 0) 0 (–1 to 1) 0.625
Missing, n 39 44
Length of hospital stay (days) to
discharge
Median (IQR) 59 (40–85) 58 (40–84) 1 (–2 to 4) 1 (–1 to 3) 0.446
Missing, n 95 97
Days in level 1 (intensive) care
Median (IQR) 8 (4–16) 8 (4–16) 0 (–1 to 1) 0 (–1 to 1) 0.963
Missing, n 87 66
Days in level 2 (high-dependency) care
Median (IQR) 10 (3–30) 9 (3–29) 0 (–1 to 1) 1 (–1 to 3) 0.420
Missing, n 83 60
Days in level 3 (special) care
Median (IQR) 29 (21–39) 30 (22–39) –1 (–2 to 1) –1 (–3 to 1) 0.216
Missing, n 75 55
a Risk ratios for binary outcomes and median differences for continuous outcomes.
b 95% CI for microbiologically confirmed or clinically suspected late-onset invasive infection, 99% CI for all other outcomes.
c Adjusted for minimisation factors: collaborating hospital, sex, gestational age at birth vs. single or multiple births,
when technically possible.
d p-value for testing whether or not adjusted RR is equal to 1 or adjusted median difference is equal to 0.
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Secondary outcomes
There were no significant differences in secondary outcomes: microbiologically confirmed infection
(RR 1.05, 99% CI 0.80 to 1.37), mortality (RR 1.05, 99% CI 0.68 to 1.63), NEC (RR 1.13, 99% CI 0.70
to 1.82), ROP (RR 0.89, 99% CI 0.57 to 1.40), BPD (RR 1.01, 99% CI 0.83 to 1.22), or a composite of
infection, major morbidity and mortality (RR 1.01, 99% CI 0.86 to 1.18). There were no differences in the
number of days of administration of antimicrobials until 34 weeks’ postmenstrual age, or in length of stay
in hospital, or length of stay in intensive care, high-dependency care or special-care settings.
Subgroup analyses
Subgroup analyses did not show any significant interactions for completed weeks’ gestation at birth or
type of enteral milk received (Table 5 and Figure 2).
Economic analysis
Given the absence of any effects on infant- or family-important outcomes (clinical effectiveness), and with
the approval of the DMC and TSC, we did not undertake the proposed within-trial economic analyses or
modelling (protocol amendment submitted).
Safety and adverse events
Table 6 summarises reported adverse events (definitions of adverse reactions and events are presented in
Appendix 7).
There were 16 SAEs reported for infants in the lactoferrin group (six severe) and 10 for infants in the sucrose
group (three severe). No infant had more than one reported event. Two SAEs, both in the lactoferrin group,
were assessed as being ‘possibly related’ to the trial intervention: one case of blood in stool (expected) and
one death following intestinal perforation likely associated with NEC (SUSAR). The remaining 24 SAEs were
considered to be unrelated to the trial intervention.
TABLE 5 Subgroup analyses for confirmed or suspected late-onset infection
Late-onset
infection
Trial group
Unadjusted RR
(95% CI)
Adjusted RRa
(95% CI) p-valueb
Lactoferrin
(n= 1098)
Placebo
(n= 1101)
Gestational age at delivery (completed weeks), n/N (%) 0.273
< 24 25/34 (73.5) 27/31 (87.1) 0.84 (0.66 to 1.07) 0.91 (0.69 to 1.20)
24 46/73 (63.0) 56/75 (74.7) 0.84 (0.68 to 1.05) 0.84 (0.69 to 1.03)
25 45/73 (61.6) 44/73 (60.3) 1.02 (0.78 to 1.34) 1.03 (0.73 to 1.45)
26 to 27 107/227 (47.1) 99/220 (45.0) 1.05 (0.86 to 1.28) 1.04 (0.85 to 1.28)
28 to 29 69/311 (22.2) 72/316 (22.8) 0.97 (0.73 to 1.30) 0.98 (0.74 to 1.29)
≥ 30 24/375 (6.4) 36/374 (9.6) 0.66 (0.40 to 1.10) 0.66 (0.42 to 1.03)
Type of milk, n/N (%) 0.400
Breast only 99/315 (31.4) 83/291 (28.5) 1.10 (0.87 to 1.40) 1.03 (0.88 to 1.21)
Mixed 199/707 (28.1) 228/710 (32.1) 0.88 (0.75 to 1.03) 0.89 (0.79 to 1.01)
Formula only 10/53 (18.9) 12/60 (20.0) 0.94 (0.45 to 2.00) 1.06 (0.58 to 1.91)
Missing, n 18 29
a Adjusted for minimisation factors: recruiting site, sex, gestational age at birth (completed weeks) and single vs. multiple birth.
b p-value for test for interaction from adjusted model.
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FIGURE 2 Subgroup analyses for confirmed or suspected late-onset invasive infection.
TABLE 6 List of SAEs reported by randomisation group
Trial group SAE
Age
(days) Brief description of event Severity
Related
to trial
Lactoferrin
(n = 1098)
1 12 Meconium ileus following one dose of IMP. Resolved with
laparotomy, no bowel removed
Moderate No
2 30 Two episodes of clinical seizures, resolved with brief course of
anticonvulsant
Moderate No
3 59 Cluster of seizures, probably related to severe Gram-negative
bacteraemia and sepsis (ultimately fatal)
Severe No
4 12 Episode of supraventricular tachycardia, resolved with
adenosine and propranolol
Mild No
5 49 Metabolic acidosis (likely renal tubular acidosis), resolved with
sodium bicarbonate
Severe No
6 20 Episode of supraventricular tachycardia, resolved with face
cooling
Mild No
7 19 Suspected NEC Moderate No
8 18 Cluster of clinical seizures, resolved with magnesium sulphate
and course of phenobarbital
Mild No
9 81 Infective exacerbation of chronic lung disease, resolved with
antibiotics and corticosteroids
Severe No
10 17 Large inferior vena caval thrombus Moderate No
11 68 Acute airway obstruction, resolved with respiratory support Severe No
12 44 Aspiration pneumonitis resolved with respiratory support Severe No
13 21 Blood in stool, unknown cause, resolved spontaneously Moderate Possibly
(expected)
14 19 Haemolytic anaemia, unknown cause, resolved spontaneously Mild No
continued
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Post hoc analyses
1. Post hoc exploratory analyses did not show any differential effects depending on the infecting
micro-organism identified for the outcome ‘microbiologically confirmed late-onset infection’ (Table 7
and Box 5).
2. Post hoc exploratory analyses did not show any between-group differences in the risk of having more
than one episodes of infection (Table 8).
3. Post hoc exploratory analyses did not show any differential effects for the primary outcome depending
on whether infants had or had not received probiotics as part of their routine care (Table 9).
TABLE 6 List of SAEs reported by randomisation group (continued )
Trial group SAE
Age
(days) Brief description of event Severity
Related
to trial
15 10 Death following intestinal perforation secondary to NEC Severe Possibly
(SUSAR)
16 27 Death attributed to Gram-negative bacteraemia Severe No
Placebo
(n = 1101)
1 61 Rib fracture secondary to osteopenia of prematurity, resolved
with supportive care and nutrient supplementation
Moderate No
2 50 Superior sagittal sinus non-occlusive thrombus, resolved with
heparin (6 weeks of treatment)
Moderate No
3 48 Hyperammonaemia, unknown cause, resolved with course of
sodium benzoate
Moderate No
4 36 Death attributed to infection and sepsis Severe No
5 24 Episode of tachycardia and ectopic beats, resolved with face
cooling and reduction in caffeine dose
Mild No
6 37 Death secondary to exacerbation of chronic lung disease
(severe BPD)
Severe No
7 26 Death attributed to severe BPD Severe No
8 57 S. aureus bacteraemia and osteomyelitis, resolved with
antibiotics
Moderate No
9 22 Episode of supraventricular tachycardia, resolved with
adenosine
Moderate No
10 6 Episode of supraventricular tachycardia, resolved with carotid
massage and adenosine
Mild No
RESULTS
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BOX 5 Classification of micro-organisms
1. Staphylococcus epidermidis.
2. Staphylococcus capitis.
3. Other coagulase-negative Staphylococci.
4. S. aureus.
5. Enterococcus faecalis.
6. Group B streptococci.
7. Enterococcus sp. (other).
8. Streptococcus sp. (other).
9. Micrococcus sp.
10. Bacillus sp.
11. Diphtheroids.
12. Streptococcus pneumoniae.
13. Propionibacterium acnes.
14. Listeria monocytogenes.
15. Other Gram-positive bacteria.
16. Escherichia coli.
17. Klebsiella sp.
18. Enterobacter sp.
19. Pseudomonas sp.
20. Serratia sp.
21. Coliforms (other).
22. Acinetobacter sp.
23. Citrobacter sp.
24. Burkholderia sp.
25. Haemophilus sp.
26. Other Gram-negative bacteria.
27. Candida albicans.
28. Candida sp. (other).
29. Other fungi.
30. Other organisms.
1–15, Gram positive; 1–3, coagulase-negative Staphylococcus group; 16–26, Gram negative; 27–29, fungi;
30, other.
TABLE 7 Microbiologically confirmed late-onset infection by classification of micro-organism
Classification of micro-organism
Trial group
Lactoferrin (n= 1098) Placebo (n= 1101)
Microbiologically confirmed late-onset invasive infection
from trial entry until hospital discharge, n/N (%)
190/1093 (17.4) 180/1089 (16.5)
At least one Gram-positive organism confirmed, n/N (%) 153/1093 (14.0) 147/1089 (13.5)
At least one CoNS group organism, n/N (%) 122/1093 (11.2) 111/1089 (10.2)
At least one Gram-negative organism confirmed, n/N (%) 46/1093 (4.2) 39/1089 (3.6)
At least one fungal organism confirmed, n/N (%) 3/1093 (0.3) 2/1089 (0.2)
At least one other organism confirmed, n/N (%) 3/1093 (0.3) 2/1089 (0.2)
Missing, n 5 12
CoNS, coagulase-negative Staphylococci.
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TABLE 8 Number of episodes of confirmed or suspected sepsis
Number of episodes
Trial group
Lactoferrin (n= 1098) Placebo (n= 1101)
Microbiologically confirmed or clinically suspected sepsis, n/N (%)
None 777/1093 (71.1) 755/1089 (69.3)
1 258/1093 (23.6) 279/1089 (25.6)
2 46/1093 (4.2) 39/1089 (3.6)
3 9/1093 (0.8) 13/1089 (1.2)
4 3/1093 (0.3) 2/1089 (0.2)
5 0/1093 (0.0) 1/1089 (0.1)
Missing, n 5 12
Microbiologically confirmed infection, n/N (%)
None 903/1093 (82.6) 909/1089 (83.5)
1 162/1093 (14.8) 155/1089 (14.2)
2 24/1093 (2.2) 23/1089 (2.1)
3 3/1093 (0.3) 2/1089 (0.2)
4 1/1093 (0.1) 0/1089 (0.0)
TABLE 9 Late-onset infection from trial entry until hospital discharge by exposure to probiotics
Trial group
Lactoferrin (n= 1098) Placebo (n= 1101)
Any record of probiotics being given, n/N (%)
Yes 99/354 (28.0) 97/329 (29.5)
No 208/728 (28.6) 227/749 (30.3)
Missing,a,b n 16 23
a In the lactoferrin trial group, 15 babies had unknown probiotic use; nine had an episode of late-onset infection, two did
not and four were unknown. One other baby with a record of probiotic use had unknown infection status.
b In the placebo trial group, 19 babies had unknown probiotic use; 10 had an episode of late-onset infection, one did not
and eight were unknown. Four other babies with a record of probiotic use had unknown infection status.
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Chapter 4 Discussion and conclusions
Summary of main findings
The ELFIN trial shows that enteral lactoferrin supplementation (150 mg/kg/day until 34 weeks’ postmenstrual
age) does not reduce the risk of late-onset infection, other morbidity or mortality in very preterm infants.
This finding contradicts the existing evidence base and illustrates why high-quality evidence from adequately
powered RCTs is needed to inform policy and practice.55 The current Cochrane review includes six RCTs,
and meta-analyses of their data suggest substantial reductions in the risk of late-onset infection and NEC
associated with lactoferrin supplementation in very preterm infants.40 However, the trials included in the
Cochrane review were small and some contained other design and methodological weaknesses that may
have introduced biases resulting in overestimation of the effect sizes.41–46 Given these concerns, the Cochrane
review authors graded the evidence for key outcomes as being of ‘low quality’ and concluded that data from
methodologically rigorous RCTs were needed to generate evidence of sufficient validity to inform policy
and practice.40
The ELFIN trial provides these data. The validity of the findings is enhanced by the quality and power of
the trial. We used best practices to limit bias, including central web-based randomisation for allocation
concealment, blinding of parents, caregivers and investigators to the group allocation, and complete
follow-up and assessment of the trial cohort with intention-to-treat analyses based on a prespecified
statistical analysis plan. The trial achieved recruitment of 2203 participants as per protocol, based on the
a priori sample size estimation. Demographic and prognostic characteristics were well-balanced between
the two groups at randomisation, with a minimisation algorithm ensuring balance for major known or
putative prognostic indicators (completed weeks of gestation, sex, single vs. multiple births) or potential
confounding influences (recruiting site). Interim analyses by the trial’s independent DMC used strict criteria
to minimise the chances of spurious findings attributable to data fluctuations before a sufficient sample size
was achieved.56,57 Adherence to the allocated interventions was high, the incidence of protocol violations
was low and outcome data were available for > 99% of the trial cohort. Event rates for the primary and
secondary outcomes were broadly similar to those that we anticipated and as have been described in other
cohort studies and RCTs involving very preterm infants.2,3 Consequently, the trial had sufficient power and
internal validity to detect reliably modest yet important effects on the risk of late-onset infection and
other morbidities.
Given the size of the ELFIN trial, with more than twice as many infants than had participated in all of the
existing trials combined, we were able to generate more precise estimates of effect size than were available
previously. The 95% CI for the relative risk estimate for the primary outcome excludes a > 14% risk reduction
and a ≥ 4% increase in risk. These estimates were consistent across completed weeks of gestation at birth,
making it unlikely that bovine lactoferrin has any important benefits for extremely preterm infants who have a
higher risk of infection. Similarly, although it is plausible that lactoferrin may have had different effects in infants
with lower levels of exposure to the immunoprotective factors present in human milk, we did not show any
interaction with the type of enteral milk feeds received during the trial period (human milk, formula or both).58
The largest previous trial, in which 331 very low birthweight infants in neonatal units in Italy participated,
showed a relative risk reduction of 66% for late-onset infection.41 Although this estimate of effect may have
been inflated by methodological weaknesses, such as the absence of predefined criteria for interim analyses,
the Italian trial differed from the ELFIN trial in other ways that could have contributed to the divergence
of findings. The participants and the intervention were broadly similar, as were enteral feeding practices,
including receipt of human breast milk versus formula milk. However, key differences in the epidemiology
of late-onset infection, as well as in infection-prevention practices and exposure to other interventions,
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may have contributed to the difference in effects size estimates shown in the two trials. Notably, the
incidence of invasive fungal infection was very high in the Italian trial (7.7% of the control group) and a
substantial proportion of the overall effect on reducing late-onset invasive infection was due to the effect on
preventing invasive fungal infection.59 In contrast, the overall incidence of late-onset fungal infection was low
in the ELFIN trial cohort (five episodes in total), consistent with that reported in UK surveillance studies.9,60
Given that a postulated mechanism of action of lactoferrin is to reduce bowel translocation of enteric
pathogens, we assessed whether or not invasive infections with particular groups of enteric organisms
were reduced.58,61 In post hoc analyses, we did not show any evidence that lactoferrin supplementation
affected the risk of late-onset infection with different groups of infecting micro-organism including
Gram-negative bacteria (mainly Escherichia coli and other Enterobacteriaceae). This finding is consistent
with the previously largest trial, which did not show an effect of lactoferrin supplementation on the
incidence of infection with Gram-negative bacteria.41
The ELFIN trial did not show any difference in the effect of lactoferrin on the risk of late-onset infection in a
post hoc subgroup analysis of infants who had or had not received probiotic supplementation during the trial
period. A previous trial and the current Cochrane review had suggested that combining supplementation of
lactoferrin with the probiotic micro-organism Lactobacillus rhamnosus GG was associated with a greater
reduction in the risk of late-onset infection (> 70%) and NEC (> 90%) than lactoferrin alone.40,41 This raised
the possibility that the immunoprotective and prebiotic properties of lactoferrin might act synergistically
with probiotic supplementation.61 Although the ELFIN trial did not show any evidence of differential effects
depending on whether or not infants had received probiotics during the trial period, the data are not sufficient
to exclude the possibility that such prebiotic–probiotic synergism exists. A recent large cluster RCT in India has
suggested that the prophylactic administration of an oral synbiotic (prebiotic fructo-oligosaccharide combined
with probiotic Lactobacillus plantarum) reduces infection and mortality in late preterm or term newborn
infants.62 We are conducting a mechanistic study in a subgroup of ELFIN trial participants to analyse whether
or not, and how, lactoferrin supplementation affects the intestinal microbiome and metabolite profile. The
study will explore changes in microbiomic and metabolomic patterns preceding disease onset including NEC
and late-onset infection.61
Limitations
The prespecified primary outcome included ‘clinically suspected’ and ‘microbiologically confirmed’ late-
onset infection. We took this pragmatic approach because of concerns about the diagnostic accuracy of
microbiological culture of blood in this population.63 Standard microbiological culture may not detect cases
of bacteraemia or fungaemia if an insufficient volume of the infant’s blood is incubated (‘false negative’).
Conversely, microbiological cultures may also generate ‘false-positive’ results if blood sampling techniques
allow entry of contaminating micro-organisms (typically from the infant’s skin). To mitigate these potential
sources of bias, we used an established consensus case definition that (1) required additional evidence of
infection (clinical signs or biomarkers) and (2) mandated that clinicians indicate an intention to treat the
infant with antibiotics or antifungals for at least 5 days.2,3
Typically, microbiological confirmation was obtained by culture of potentially pathogenic bacteria or
fungi from an infant’s blood or CSF sample, or from another normally sterile tissue space. The outcome
definition included infection with coagulase-negative Staphylococci, provided that these were not a mixed
flora but excluded micro-organisms that were likely to be skin contaminants (diphtheroids, micrococci or
propionibacteria). This approach is consistent with standard clinical practice and surveillance protocols in
the UK and elsewhere. The case definition of late-onset infection did not include urinary tract infection or
radiologically confirmed pneumonia, as these are not accurate and reliable in very preterm infants in the
absence of bacteraemia.64
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Secondary outcomes
Estimates for the secondary outcomes indicated consistently that lactoferrin supplementation does not have
important effects on the risk of major morbidities. We prespecified an analysis of the effect on a composite
of infection, NEC, BPD, ROP and mortality. The adjusted RR point estimate for this secondary outcome
was 1.01, with a 99% CI excluding a > 6% reduction and a ≥ 8% increase in risk. We plan to increase
the precision of these estimates of effect on rarer secondary outcomes by combining these data in a
meta-analysis with other trials, including a recently completed Australasia RCT (n = 1500) of bovine
lactoferrin supplementation for very low birthweight infants (Lactoferrin Infant Feeding Trial; see
www.anzctr.org.au/ACTRN12611000247976.aspx).65
Cost analyses
As late-onset infection and NEC are the major reasons for receipt of invasive interventions and higher levels
of ‘categories of care’ in very preterm infants, it is not surprising that we did not show any effects on the level
of exposure to antimicrobial agents or on the duration of hospitalisation or stay in intensive or special care
settings. Given that the ELFIN trial did not show any differences between groups in the risk of morbidity or
on levels of care received, we did not undertake detailed analyses of health-care costs as had been proposed
in our approved funding application and trial protocol. We did not conduct a within-trial health economic
analysis or use these data in a model to explore long-term family and health service costs, as these are driven
mainly by the consequences of infection and other morbidity during the initial hospitalisation. Without
evidence of clinical effectiveness on these infant-important outcomes, we considered a cost-effectiveness
analysis of lactoferrin supplementation to be futile.66
Qualitative analysis and parent views
A qualitative analysis and exploration of participants’ parents views and expectations has been undertaken
in collaboration with the SIFT investigators.48 Given that this study included SIFT participants predominantly
(with few ELFIN trial participants), the findings will be reported within the SIFT report.
Long-term outcomes
We do not plan to apply for permission and additional funding to assess longer-term outcomes of trial
participants. We specified in our funding application and protocol that if the trial did not detect statistically
significant or clinically important differences in the in-hospital outcomes then follow-up will not be undertaken
because any between-group differences in growth and neurodevelopmental outcomes are predicated largely
on differences in the incidence of late-onset infections, NEC and associated morbidities.5,6,11 As these were not
shown, there is no longer an impelling rationale for expecting lactoferrin supplementation to have an impact
on long-term growth or development.
Applicability
The ELFIN trial findings are likely to be applicable in the UK and internationally. Participants were enrolled
in 37 neonatal units across the country, providing broad geographical, social and ethnic representation.
Many infants who were enrolled in a recruiting site were transferred subsequently to another neonatal unit,
which was typically closer to the family home, for ongoing care. Trial participation continued in another
97 neonatal units and this practice mirrors managed clinical network care pathways for very preterm infants
in the UK.
The trial population was representative of very preterm infants cared for within health-care facilities in
well-resourced health services and included a substantial proportion of extremely preterm infants (37%)
and infants with other putative risk factors for neonatal morbidity, such as prolonged rupture of maternal
amniotic membranes (25%) and evidence of absent or reverse end diastolic flow in the umbilical artery
(12%). Overall, about 30% of participants acquired a microbiologically confirmed or clinically suspected
late-onset infection, and about 17% in total had a microbiologically confirmed infection, consistent with
rates reported from cohort studies and other RCTs. Similarly, the incidence of NEC (about 5%) was similar
to rates reported in large, population-based surveillance and cohort studies and RCTs.67
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Implications for practice
The ELFIN trial does not support the routine use of enteral bovine lactoferrin supplementation to prevent
late-onset infection or other morbidity or mortality in very preterm infants.
Implications for research
Research efforts should continue to investigate the aetiology, epidemiology and pathogenesis of late-onset
infection and related morbidities, and to develop, refine and assess other interventions that may prevent or
reduce adverse acute and long-term consequences for very preterm infants and their families.
DISCUSSION AND CONCLUSIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
Acknowledgements
We are grateful to all of the parents of participating infants and to all staff and carers in recruiting andcontinuing care sites. We thank the members of the independent DMC and TSC, Yan Hunter-Blair
and colleagues at the Newcastle Specials Pharmacy team, Tatua Dairy Co-operative, New Zealand, and the
administrative and support colleagues at the NPEU CTU.
Independent Trial Steering Committee
Richard Cooke (chairperson), Fan Hutchison (deputy chairperson), Andrew Ewer, Jennifer Hellier and
Paul Mannix.
Independent Data Monitoring Committee
Henry Halliday (chairperson), Nim Subhedar, Michael Millar, Alison Baum and Mike Bradburn.
Ethics approval
National Research Ethics Service Committee East Midlands – Nottingham 2 (reference number 13/EM/0118,
02/04/2013).
Contributions of authors
James Griffiths (Trial Manager), Paula Jenkins (Trial Research Nurse), Monika Vargova (Administrator
and Data Co-ordinator), Ursula Bowler (Senior Trials Manager), Andrew King (Head of Trials
Programming), David Murray (Senior Trials Programmer), Paul T Heath (Co-investigator, chairperson of
the blinded end-point review committee) and William McGuire (Chief Investigator) were responsible for
the data collection and management.
Edmund Juszczak (NPEU CTU Director), Janet Berrington (Co-investigator), Nicholas Embleton
(Co-investigator), Jon Dorling (Co-investigator), Paul T Heath, William McGuire and Sam Oddie
(Co-investigator) were responsible for the study design.
Louise Linsell (Trial Statistician), Christopher Partlett (Trial Statistician), Edmund Juszczak,
Paul T Heath and William McGuire were responsible for the data analysis.
Mehali Patel (Patient and Public Involvement Representative), Edmund Juszczak, Janet Berrington,
Nicholas Embleton, Paul T Heath, William McGuire and Sam Oddie were responsible for the data
interpretation.
James Griffiths, Edmund Juszczak, Louise Linsell, Christopher Partlett andWilliam McGuire were
responsible for the report writing.
All authors approved the final draft of the manuscript.
DOI: 10.3310/hta22740 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 74
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Griffiths et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29
Publications
ELFIN Trial Investigators Group. Lactoferrin immunoprophylaxis for very preterm infants. Arch Dis Child
Fetal Neonatal Ed 2013;98:F2–4.
The ELFIN Trial Investigators Group. Enteral lactoferrin supplementation for very preterm infants:
a randomised controlled trial. Lancet 2018; in press.
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Please note that
exclusive use will be retained until the publication of major outputs. Access to anonymised data may be
granted following review.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
References
1. Duley L, Uhm S, Oliver S, Preterm Birth Priority Setting Partnership Steering Group. Top 15 UK
research priorities for preterm birth. Lancet 2014;383:2041–2. https://doi.org/10.1016/S0140-6736
(14)60989-2
2. Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al. Neonatal infections in
England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011;96:F9–F14.
https://doi.org/10.1136/adc.2009.178798
3. Cailes B, Kortsalioudaki C, Buttery J, Pattnayak S, Greenough A, Matthes J, et al. Epidemiology of
UK neonatal infections: the neonIN infection surveillance network. Arch Dis Child Fetal Neonatal Ed
2018;103:F547–53. https://doi.org/10.1136/archdischild-2017-313203
4. Chapman RL, Faix RG. Persistent bacteremia and outcome in late onset infection among infants
in a neonatal intensive care unit. Pediatr Infect Dis J 2003;22:17–21. https://doi.org/10.1097/
01.inf.0000042922.10767.10
5. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the
preterm infant. Curr Opin Infect Dis 2006;19:290–7. https://doi.org/10.1097/01.qco.0000224825.
57976.87
6. Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Trial of Indomethacin
Prophylaxis in Preterms Investigators. Using a count of neonatal morbidities to predict poor outcome
in extremely low birth weight infants: added role of neonatal infection. Pediatrics 2009;123:313–18.
https://doi.org/10.1542/peds.2008-0377
7. Gordon A, Isaacs D. Late onset neonatal Gram-negative bacillary infection in Australia and New
Zealand: 1992–2002. Pediatr Infect Dis J 2006;25:25–9. https://doi.org/10.1097/01.inf.0000195628.
35980.2e
8. Isaacs D, Fraser S, Hogg G, Li HY. Staphylococcus aureus infections in Australasian neonatal
nurseries. Arch Dis Child Fetal Neonatal Ed 2004;89:F331–5. https://doi.org/10.1136/adc.2002.
009480
9. Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Invasive fungal infection in very low birthweight
infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed 2006;91:F188–92.
https://doi.org/10.1136/adc.2005.082024
10. Isaacs D; Australasian Study Group for Neonatal Infections. A ten year, multi-centre study of coagulase
negative staphylococcal infections in Australasian neonatal units. Arch Dis Child Fetal Neonatal Ed
2003;88:F89–93. https://doi.org/10.1136/fn.88.2.F89
11. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, Higgins RD, National Institute
of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and
growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA
2004;292:2357–65. https://doi.org/10.1001/jama.292.19.2357
12. Stoll BJ, Hansen N. Infections in VLBW infants: studies from the NICHD Neonatal Research Network.
Semin Perinatol 2003;27:293–301. https://doi.org/10.1016/S0146-0005(03)00046-6
13. Fowlie PW, Schmidt B. Diagnostic tests for bacterial infection from birth to 90 days – a systematic
review. Arch Dis Child Fetal Neonatal Ed 1998;78:F92–8. https://doi.org/10.1136/fn.78.2.F92
14. Malik A, Hui CP, Pennie RA, Kirpalani H. Beyond the complete blood cell count and C-reactive
protein: a systematic review of modern diagnostic tests for neonatal sepsis. Arch Pediatr Adolesc
Med 2003;157:511–16. https://doi.org/10.1001/archpedi.157.6.511
DOI: 10.3310/hta22740 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 74
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Griffiths et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
15. Buttery JP. Blood cultures in newborns and children: optimising an everyday test. Arch Dis Child
Fetal Neonatal Ed 2002;87:F25–8. https://doi.org/10.1136/fn.87.1.F25
16. Gordon A, Isaacs D. Late-onset infection and the role of antibiotic prescribing policies. Curr Opin
Infect Dis 2004;17:231–6. https://doi.org/10.1097/00001432-200406000-00010
17. Isaacs D. Unnatural selection: reducing antibiotic resistance in neonatal units. Arch Dis Child Fetal
Neonatal Ed 2006;91:F72–4. https://doi.org/10.1136/adc.2005.074963
18. Murphy BP, Armstrong K, Ryan CA, Jenkins JG. Benchmarking care for very low birthweight infants
in Ireland and Northern Ireland. Arch Dis Child Fetal Neonatal Ed 2010;95:F30–5. https://doi.org/
10.1136/adc.2009.160002
19. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet 2017;390:1770–80. https://doi.org/
10.1016/S0140-6736(17)31002-4
20. Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack.
Cell Mol Life Sci 2005;62:2576–87. https://doi.org/10.1007/s00018-005-5372-0
21. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin structure and
functions. Adv Exp Med Biol 2008;606:163–94. https://doi.org/10.1007/978-0-387-74087-4_6
22. Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system.
Virulence 2010;1:440–64. https://doi.org/10.4161/viru.1.5.12983
23. Reddy V, Bhaskaram C, Raghuramulu N, Jagadeesan V. Antimicrobial factors in human milk.
Acta Paediatr Scand 1977;66:229–32. https://doi.org/10.1111/j.1651-2227.1977.tb07838.x
24. Legrand D. Overview of lactoferrin as a natural immune modulator. J Pediatr 2016;173:S10–5.
https://doi.org/10.1016/j.jpeds.2016.02.071
25. González-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin: structure, function and
applications. Int J Antimicrob Agents 2009;33:301.e1–8. https://doi.org/10.1016/j.ijantimicag.2008.
07.020
26. Ochoa TJ, Cleary TG. Effect of lactoferrin on enteric pathogens. Biochimie 2009;91:30–4.
https://doi.org/10.1016/j.biochi.2008.04.006
27. Tian H, Maddox IS, Ferguson LR, Shu Q. Influence of bovine lactoferrin on selected probiotic bacteria
and intestinal pathogens. Biometals 2010;23:593–6. https://doi.org/10.1007/s10534-010-9318-0
28. Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des
2009;15:1956–73. https://doi.org/10.2174/138161209788453202
29. Berlutti F, Schippa S, Morea C, Sarli S, Perfetto B, Donnarumma G, Valenti P. Lactoferrin downregulates
pro-inflammatory cytokines upexpressed in intestinal epithelial cells infected with invasive or noninvasive
Escherichia coli strains. Biochem Cell Biol 2006;84:351–7. https://doi.org/10.1139/o06-039
30. Wakabayashi H, Takakura N, Yamauchi K, Tamura Y. Modulation of immunity-related gene expression
in small intestines of mice by oral administration of lactoferrin. Clin Vaccine Immunol 2006;13:239–45.
https://doi.org/10.1128/CVI.13.2.239-245.2006
31. Buccigrossi V, de Marco G, Bruzzese E, Ombrato L, Bracale I, Polito G, Guarino A. Lactoferrin induces
concentration-dependent functional modulation of intestinal proliferation and differentiation.
Pediatr Res 2007;61:410–14. https://doi.org/10.1203/pdr.0b013e3180332c8d
32. Raghuveer TS, McGuire EM, Martin SM, Wagner BA, Rebouché CJ, Buettner GR, Widness JA.
Lactoferrin in the preterm infants’ diet attenuates iron-induced oxidation products. Pediatr Res
2002;52:964–72. https://doi.org/10.1203/00006450-200212000-00024
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
33. Magnuson JS, Henry JF, Yip TT, Hutchens TW. Structural homology of human, bovine, and porcine
milk lactoferrins: evidence for shared antigenic determinants. Pediatr Res 1990;28:176–81.
https://doi.org/10.1203/00006450-199028020-00019
34. Vorland LH, Ulvatne H, Andersen J, Haukland H, Rekdal O, Svendsen JS, Gutteberg TJ. Lactoferricin
of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J
Infect Dis 1998;30:513–17. https://doi.org/10.1080/00365549850161557
35. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrin-derived peptide with antimicrobial,
antiviral, antitumor and immunological properties. Cell Mol Life Sci 2005;62:2588–98.
https://doi.org/10.1007/s00018-005-5373-z
36. Office of Food Additive Safety. GRAS Notification. Food and Drug Administration. URL:
www.accessdata.fda.gov/scripts/fcn/gras_notices/204568A.pdf28 (accessed 23 March 2018)
37. Appel MJ, van Veen HA, Vietsch H, Salaheddine M, Nuijens JH, Ziere B, de Loos F. Sub-chronic
(13-week) oral toxicity study in rats with recombinant human lactoferrin produced in the milk of
transgenic cows. Food Chem Toxicol 2006;44:964–73. https://doi.org/10.1016/j.fct.2005.11.012
38. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on bovine
lactoferrin. EFSA J 2012;10:2701. https://doi.org/10.2903/j.efsa.2012.2701
39. Lingappan K, Arunachalam A, Pammi M. Lactoferrin and the newborn: current perspectives.
Expert Rev Anti Infect Ther 2013;11:695–707. https://doi.org/10.1586/14787210.2013.811927
40. Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing
enterocolitis in preterm infants. Cochrane Database Syst Rev 2017;6:CD007137. https://doi.org/
10.1002/14651858.CD007137.pub5
41. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al. Bovine lactoferrin
supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized
trial. JAMA 2009;302:1421–8. https://doi.org/10.1001/jama.2009.1403
42. Barrington KJ, Assaad MA, Janvier A. The Lacuna Trial: a double-blind randomized controlled
pilot trial of lactoferrin supplementation in the very preterm infant. J Perinatol 2016;36:666–9.
https://doi.org/10.1038/jp.2016.24
43. Akin IM, Atasay B, Dogu F, Okulu E, Arsan S, Karatas HD, et al. Oral lactoferrin to prevent nosocomial
sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells. Am J
Perinatol 2014;31:1111–20. https://doi.org/10.1055/s-0034-1371704
44. Kaur G, Gathwala G. Efficacy of bovine lactoferrin supplementation in preventing late-onset
sepsis in low birth weight neonates: a randomized placebo-controlled clinical trial. J Trop Pediatr
2015;61:370–6. https://doi.org/10.1093/tropej/fmv044
45. Ochoa TJ, Zegarra J, Cam L, Llanos R, Pezo A, Cruz K, et al. Randomized controlled trial of lactoferrin
for prevention of sepsis in peruvian neonates less than 2500 g. Pediatr Infect Dis J 2015;34:571–6.
https://doi.org/10.1097/INF.0000000000000593
46. Sherman MP, Adamkin DH, Niklas V, Radmacher P, Sherman J, Wertheimer F, Petrak K. Randomized
controlled trial of talactoferrin oral solution in preterm infants. J Pediatr 2016;175:68–73.e3.
https://doi.org/10.1016/j.jpeds.2016.04.084
47. The ELFIN Trial Investigators Group. Summary protocol for a multi-centre randomised controlled
trial of enteral lactoferrin supplementation in newborn very preterm infants (ELFIN). Neonatology
2018;114:142–8. https://doi.org/10.1159/000488927
48. Abbott J, Berrington J, Bowler U, Boyle E, Dorling J, Embleton N, et al. The speed of increasing
milk feeds: a randomised controlled trial. BMC Pediatr 2017;17:39. https://doi.org/10.1186/
s12887-017-0794-z
DOI: 10.3310/hta22740 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 74
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Griffiths et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33
49. Allmark P, Spedding M. Clinical trials in neonates: ethical issues. Semin Fetal Neonatal Med 2007;
12:318–23. https://doi.org/10.1016/j.siny.2007.01.023
50. European Medicines Agency. Report on the Expert Meeting on Neonatal and Paediatric Sepsis 2010.
URL: www.ema.europa.eu/docs/en_GB/document_library/Report/2010/12/WC500100199.pdf
(accessed 23 March 2018).
51. Modi N, Doré CJ, Saraswatula A, Richards M, Bamford KB, Coello R, Holmes A. A case definition
for national and international neonatal bloodstream infection surveillance. Arch Dis Child Fetal
Neonatal Ed 2009;94:F8–12. https://doi.org/10.1136/adc.2007.126458
52. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr
Clin North Am 1986;33:179–201. https://doi.org/10.1016/S0031-3955(16)34975-6
53. ICROP. An International Classification of Retinopathy of Prematurity. Pediatrics 1984;74:127–33.
54. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the
National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics
2005;116:1353–60. https://doi.org/10.1542/peds.2005-0249
55. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008;19:640–8.
https://doi.org/10.1097/EDE.0b013e31818131e7
56. DAMOCLES Study Group, NHS Health Technology Assessment Programme. A proposed charter for
clinical trial data monitoring committees: helping them to do their job well. Lancet 2005;365:711–22.
https://doi.org/10.1016/S0140-6736(05)70939-9
57. Guyatt GH, Briel M, Glasziou P, Bassler D, Montori VM. Problems of stopping trials early. BMJ
2012;344:e3863. https://doi.org/10.1136/bmj.e3863
58. Embleton ND, Berrington JE, McGuire W, Stewart CJ, Cummings SP. Lactoferrin: Antimicrobial
activity and therapeutic potential. Semin Fetal Neonatal Med 2013;18:143–9. https://doi.org/
10.1016/j.siny.2013.02.001
59. Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG, et al. Bovine lactoferrin prevents
invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics
2012;129:116–23. https://doi.org/10.1542/peds.2011-0279
60. Oeser C, Vergnano S, Naidoo R, Anthony M, Chang J, Chow P, et al. Neonatal invasive fungal
infection in England 2004-2010. Clin Microbiol Infect 2014;20:936–41. https://doi.org/10.1111/
1469-0691.12578
61. Embleton ND, Berrington JE, Dorling J, Ewer AK, Juszczak E, Kirby JA, et al. Mechanisms affecting
the gut of preterm infants in enteral feeding trials. Front Nutr 2017;4:14. https://doi.org/10.3389/
fnut.2017.00014
62. Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, Chandel DS, et al. A randomized synbiotic
trial to prevent sepsis among infants in rural India. Nature 2017;548:407–12. https://doi.org/
10.1038/nature23480
63. Oeser C, Lutsar I, Metsvaht T, Turner MA, Heath PT, Sharland M. Clinical trials in neonatal sepsis.
J Antimicrob Chemother 2013;68:2733–45. https://doi.org/10.1093/jac/dkt297
64. Tamim MM, Alesseh H, Aziz H. Analysis of the efficacy of urine culture as part of sepsis evaluation
in the premature infant. Pediatr Infect Dis J 2003;22:805–8. https://doi.org/10.1097/01.inf.
0000083822.31857.43
65. Martin A, Ghadge A, Manzoni P, Lui K, Brown R, Tarnow-Mordi W, LIFT Collaborative Study Group.
Protocol for the Lactoferrin Infant Feeding Trial (LIFT): a randomised trial of adding lactoferrin to
the feeds of very-low birthweight babies prior to hospital discharge. BMJ Open 2018;8:e023044.
https://doi.org/10.1136/bmjopen-2018-023044
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
66. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for
health care decision making? Health Econ 2006;15:677–87. https://doi.org/10.1002/hec.1093
67. Battersby C, Santhalingam T, Costeloe K, Modi N. Incidence of neonatal necrotising enterocolitis in
high-income countries: a systematic review. Arch Dis Child Fetal Neonatal Ed 2018;103:F182–9.
https://doi.org/10.1136/archdischild-2017-313880
68. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis
in preterm infants. Cochrane Database Syst Rev 2015;2:CD007137. https://doi.org/10.1002/
14651858.CD007137.pub4
DOI: 10.3310/hta22740 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 74
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Griffiths et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35

Appendix 1 Recruiting neonatal units
Recruiting sites PI Research nurse
Altnagelvin Area Hospital Mary Ledwidge Julie Brown
Birmingham Heartlands Hospital Imogen Story Natalie Albrighton
Birmingham Women’s Hospital Gemma Holder Rachel Jackson/Elizabeth Simcox/
Heather Barrow
Bradford Royal Infirmary Sam Oddie Kelly Young/Trudy Booth
Calderdale Royal Hospital Pamela Ohadike Salamiah Burgess
University Hospital Coventry Sarah Ellis Kerri McGowan/Nicola Watts
Derriford Hospital, Plymouth Rima Vaikute Sarah-Jane Sharman
Great Western Hospital, Swindon Girish Gowda Rebecca Elliott-Jones
Hull Royal Infirmary Helen Yates Leanne Sherris
James Cook University Hospital, Middlesbrough Shalabh Garg Amanda Forster/Helena Smith
Jessop Wing – Sheffield Teaching Hospital Liz Pilling Pauline Bayliss
John Radcliffe Hospital, Oxford Charles Roehr Sheula Barlow/Sharon Baugh
Leeds General Infirmary Kathryn Johnson Suzanne Laing
Leicester Royal Infirmary Elaine Boyle Marie Hubbard/Rosalind Astles
Norfolk and Norwich University Hospital Paul Clarke Karen Few
Nottingham City Hospital Dushyant Batra Yvonne Hooton/Helen Navarra
Pinderfields Hospital, Wakefield David Gibson Gail Castle
Princess Anne Hospital, Southampton Mark Johnson Jenny Pond/Philippa Crowley/
Jane Rhodes-Kitson
Princess Royal Maternity Hospital, Glasgow Helen Mactier Isobel Crawford
Queen Alexandra Hospital, Portsmouth Tim Scorrer Michelle Pople/Michele Voysey
Nottingham University Hospital Jon Dorling Yvonne Hooton/Helen Navarra
Royal Cornwall Hospital, Truro Yadlapalli Kumar Barbara Bromage
Royal Devon and Exeter NHS Foundation Trust David Bartle Jacqui Tipper/Jenny Cunningham
Royal Hospital for Children, Glasgow Colin Peters Lorna McKay
Royal Infirmary of Edinburgh David Quine Lynn Clark
Royal Maternity Hospital, Belfast Stanley Craig Muriel Millar
Royal Preston Hospital Richa Gupta Claire Lodge
Royal Victoria Infirmary, Newcastle upon Tyne Nick Embleton Julie Groombridge
Singleton Hospital, Swansea Jean Matthes Amanda Cook
St George’s Hospital, London Nigel Kennea Vana Wardley/Naomi Hayward
St Peter’s Hospital, Chertsey Peter Reynolds Nicky Holland
Sunderland Royal Hospital Ruppa Geethanath Natalie Talbot
University Hospital of North Tees Sundaram Janakiraman Alex Ramshaw
Victoria Hospital, Kirkcaldy Sean Ainsworth Debbie Johnston
William Harvey Hospital, Ashford Vimal Vasu Shermi George
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Recruiting sites PI Research nurse
Wishaw General Hospital CM Manjunatha Denise Vigni
York District Hospital William McGuire Anna Clayton
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Appendix 2 Continuing care sites
Accrington Victoria Hospital; Airedale General Hospital; Antrim Area Hospital; Barnsley Hospital; BasildonUniversity Hospital; Basingstoke and North Hampshire Hospital; Bassetlaw Hospital; Birmingham
Children’s Hospital; Birmingham City Hospital; Borders General Hospital; Broomfield Hospital; Burnley
General Hospital; Chesterfield Royal Hospital; Chorley and South Ribble Hospital; Colchester General
Hospital; County Hospital, Stafford; Craigavon Area Hospital; Crosshouse University Hospital; Croydon
University Hospital; Darlington Memorial Hospital; Diana Princess of Wales Hospital, Grimsby; Doncaster
Royal Infirmary; Dorset County Hospital; Dumfries and Galloway Royal Infirmary; Forth Valley Royal
Hospital; George Eliot Hospital, Nuneaton; Glangwili General Hospital; Gloucestershire Royal Hospital;
Good Hope Hospital, Sutton Coldfield; Great Ormond Street Hospital for Children, London; Harrogate District
Hospital; Horton General Hospital; Ipswich Hospital; James Paget University Hospital, Great Yarmouth;
King’s Mill Hospital, Sutton-in-Ashfield; Lincoln County Hospital; Liverpool Women’s Hospital; Maidstone
Hospital; Medway Maritime Hospital, Gillingham; Milton Keynes General Hospital; Musgrove Park Hospital,
Taunton; Northampton General Hospital; North Manchester General Hospital; Northumbria Specialist
Emergency Care Hospital, Cramlington; Pilgrim Hospital, Boston; Poole Hospital; Princess of Wales Hospital,
Bridgend; Queen Elizabeth Hospital, Gateshead; Queen Elizabeth Hospital, King’s Lynn; Queen Elizabeth
The Queen Mother Hospital, Margate; Queen’s Hospital, Burton on Trent; Queen’s Hospital, Romford;
Raigmore Hospital, Inverness; Rotherham General Hospital; Royal Berkshire Hospital, Reading; Royal
Blackburn Hospital; Royal Bolton Hospital; Royal Derby Hospital; Royal Hampshire County Hospital,
Winchester; Royal Oldham Hospital; Royal Shrewsbury Hospital; Royal Surrey County Hospital, Guildford;
Russells Hall Hospital, Dudley; Salisbury District Hospital; Scarborough General Hospital; Scunthorpe
General Hospital; Southend Hospital, Westcliff-on-Sea; Southport Hospital; South Tyneside District Hospital,
South Shields; Stepping Hill Hospital, Stockport; St John’s Hospital, Livingstone; St Mary’s Hospital,
Newport; Stoke Mandeville Hospital, Aylesbury; St Richard’s Hospital, Chichester; The County Hospital,
Hereford; The Cumberland Infirmary, Carlisle; Torbay Hospital, Torquay; Tunbridge Wells Hospital; Ulster
Hospital, Dundonald; University Hospital Lewisham; University Hospital of North Durham, Durham;
Warwick Hospital; Watford General Hospital; West Cumberland Hospital, Whitehaven; West Suffolk
Hospital, Bury St Edmunds; Withybush General Hospital, Haverfordwest; Worcestershire Royal Hospital,
Worcester; Worthing Hospital; and Wrightington Hospital, Wigan.
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Appendix 3 Preparation of Investigational
Medicinal Product for administration
1. Verify that the pack ID number on the pharmacy pot matches the pack ID allocated to the infant
(stated on the randomisation confirmation e-mail and to be recorded on the daily dosing log).
2. Add 4 ml of sterile water (supplied in plastic vial) plus 1 ml of either expressed breast milk or formula
(if expressed breast milk is not available) to the pharmacy pot, which contains 375 mg of either
lactoferrin or sucrose placebo.
3. Seal the pot with the lid and shake vigorously by hand for 30 seconds.
4. Leave the pot at room temperature for 30 minutes.
5. Using a syringe, draw off suspension (2 ml/kg body weight up to a maximum of 4 ml) for nasogastric/
orogastric or oral administration (via spoon/cup/syringe or bottle). [Participating centres were supplied
with oral syringes if their standard oral syringe was not compatible with the lactoferrin/placebo
pot insert].
6. Trial IMP normally to be given once daily. For very small infants, clinicians or caregivers may choose to
administer the daily dose in two aliquots. If these are to be given > 30 minutes apart, then a fresh dose
should be prepared as above for each.
7. If there was any concern about acute intestinal inflammation or perforation then the dose could be
omitted. Whether or not doses were omitted at other times when the infant was unwell or demonstrated
enteral feeds intolerance was at the discretion of the attending consultant paediatrician.
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Appendix 4 Case definition of necrotising
enterocolitis
Necrotising enterocolitis may be diagnosed at surgery, at post-mortem examination or clinically andradiologically using the following criteria.
At least one of the following clinical signs present:
l bilious gastric aspirate or emesis
l abdominal distension
l occult or gross blood in stool (no fissure).
In addition, at least one of the following radiological features present:
l pneumatosis intestinalis
l hepatobiliary gas
l pneumoperitoneum.
Infants who satisfy the definition of NEC above but are found at surgery or post-mortem examination for
that episode to have a ‘focal gastrointestinal perforation’ should be coded as having ‘focal gastrointestinal
perforation’, not as having NEC.
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Appendix 5 British Association of Perinatal
Medicine: ‘categories of care’
URL: www.bapm.org/sites/default/files/files/CatsofcarereportAug11.pdf (accessed 29 June 2018).
Intensive care
General principle: this is care provided for infants who are the most unwell or unstable and have the
greatest needs in relation to staff skills and staff-to-patient ratios.
Definition of intensive care day
Any day when an infant receives any form of mechanical respiratory support via a tracheal tube.
Both non-invasive ventilation [e.g. nasal continuous positive airways pressure (CPAP)] and parenteral nutrition.
l Day of surgery (including laser therapy for ROP).
l Day of death.
l Any day receiving any of the following:
¢ presence of an umbilical arterial line
¢ presence of an umbilical venous line
¢ presence of a peripheral arterial line
¢ insulin infusion
¢ presence of a chest drain
¢ exchange transfusion
¢ therapeutic hypothermia
¢ prostaglandin infusion
¢ presence of replogle tube
¢ presence of epidural catheter
¢ presence of silo for gastroschisis
¢ presence of external ventricular drain
¢ dialysis (any type).
High-dependency care
General principle: this is care provided for infants who require highly skilled staff but where the ratio of
nurses to patients is less than that in intensive care.
Definition of high-dependency care day
Any day when an infant does not fulfil the criteria for intensive care where any of the following apply:
Any day when an infant receives any form of non invasive respiratory support (e.g. nasal CPAP).
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Any day receiving any of the following:
parenteral nutrition
continuous infusion of drugs (except prostaglandin and/or insulin)
presence of a central venous or long line (peripherally inserted central catheter)
presence of a tracheostomy
presence of a urethral or suprapubic catheter
presence of transanastomotic tube following oesophageal atresia repair
presence of nasopharyngeal airway/nasal stent
observation of seizures or cerebral function monitoring
barrier nursing
ventricular tap.
Special care
General principle: special care is provided for infants who require additional care delivered by the neonatal
service but do not require either intensive or high-dependency care.
Definition of special care day
Any day where an infant does not fulfil the criteria for intensive or high-dependency care and requires any
of the following:
oxygen by nasal cannula
feeding by nasogastric, jejunal tube or gastrostomy
continuous physiological monitoring (excluding apnoea monitors only)
care of a stoma
presence of intravenous cannula
phototherapy
special observation of physiological variables at least 4 hourly.
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Appendix 6 Data collection forms
URL: www.npeu.ox.ac.uk/elfin/data-collection-forms (accessed 24 July 2018).
Form Purpose
Trial entry form The entry form contains sections to be completed before, during and after randomisation,
and collects the infant’s baseline characteristics
Daily dosing log To be completed daily during the treatment period (once the infant receives milk feeds of
12 ml/kg/day until 34 weeks’ postmenstrual age) to document the administration of
lactoferrin or placebo, type of milk given and use of antibiotic and antifungal drugs
Late-onset infection form To report each episode of microbiologically confirmed or clinically suspected late-onset
invasive infection
Gut signs form To report each episode whenever an infant has received ≥ 5 days of treatment for gut signs,
if they are transferred with gut signs, or if they have died from gut signs
Hospital transfer and
discharge form
To be completed by each recruiting, continuing care or data collection site whenever a
participating infant is discharged home, is transferred to another unit, or has died
Discontinuation of
intervention
To be completed if lactoferrin or placebo is permanently discontinued early (by clinician or
parental decision) or where parents choose to withdraw their infant from the trial
SAE/SUSAR form Should be completed for all SAEs that are ‘unexpected’ and sent to the NPEU CTU within
24 hours of becoming aware of the event
Incident form To report any deviation from the protocol, trial-specific procedures or good clinical practice
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Appendix 7 Safety reporting: definitions
Adverse event
Any untoward medical occurrence in a patient or clinical investigation participant who has been administered
a medicinal product, which does not necessarily have to have a causal relationship with this treatment
(the study medication).
An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory
finding), symptom or disease temporally associated with the use of the study medication, whether or not it
is considered to be related to the study medication.
Adverse reaction
All untoward and unintended responses to a medicinal product related to any dose.
The phrase ‘responses to a medicinal product’ means that a causal relationship between a study medication
and an adverse event is at least a reasonable possibility (i.e. the relationship cannot be ruled out). All cases
judged by either the reporting medically qualified professional or the sponsor as having a reasonable
suspected causal relationship to the study medication qualify as adverse reactions.
Serious adverse event
Adverse events are defined as serious if they:
l result in death
l are life-threatening
l require inpatient hospitalisation or prolongation of existing hospitalisation
l result in persistent or significant disability/incapacity
l are a congenital anomaly/birth defect
l are other important medical events.
Note that other events that may not result in death, are not life-threatening or do not require hospitalisation
may be considered SAEs when, based on medical judgement, the event may jeopardise the patient
and may require medical or surgical intervention to prevent one of the outcomes listed above. The term
‘life-threatening’ refers to an event in which the patient was at risk of death at the time of the event; it does
not refer to an event that hypothetically might have caused death if it were more severe.
Serious adverse reaction
A serious adverse reaction (SAR) is a SAE that is considered to have been caused by the administration of
the trial medication. For a SAE to be considered a SAR, there must be a reasonable probability that it was
related to the administration of the IMP.
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Suspected unexpected serious adverse reaction
This is a SAR, the nature or severity of which is not consistent with the known safety profile of the trial
medication (e.g. investigator’s brochure for an unapproved investigational product or summary of product
characteristics for an approved product).
Foreseeable (‘expected’) serious adverse events
The following are SAEs that could be reasonably expected to occur in this population of infants during the
course of the trial or form part of the outcome data. They do not require reporting by the trial centres
as SAEs:
l death (unless unexpected in this population)
l NEC or focal intestinal perforation
l BPD or chronic lung disease
l intracranial abnormality (haemorrhage or focal white matter damage) on cranial ultrasound scan or
other imaging
l pulmonary haemorrhage
l patent ductus arteriosus
l ROP.
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Appendix 8 Summary of changes to the
study protocol
P rotocol is available at www.npeu.ox.ac.uk/elfin/protocols (accessed 24 July 2018) and in theNeonatology article.47
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Amendment
Date of REC
favourable
opinion
Date of
MHRA approval Document Description
Amend 1 14 October 2013 –
(Prior to Clinical
Trials Authorisation
application)
Protocol version 2 l The procedure for making up the intervention was changed to reduce the total fluid volume
to 5ml (1 ml milk + 4ml water). The concentration of the solution to be administered
(75 mg/ml) and dose (150mg/kg/day) is unchanged from the original application
l The exclusion criteria were clarified. One serious congenital anomaly is sufficient for
exclusion (changed from anomalies)
l Clarification was added that it is acceptable to recruit infants to both the ELFIN trial and SIFT
l The definitions of microbiologically confirmed and clinically suspected late-onset infection
were edited for clarity
l ‘Multiple births’ was added as a minimisation factor at randomisation
l Text was added to explain that participants will be ‘flagged’ by the Health and Social Care
Information Centre
l Changes to appendix 3: IMP management explaining the procedure for making up
the intervention
l The projected recruitment rate in appendix 4 was revised slightly upwards
IMP dossier version 2 l Ampoules of sterile water will be sourced from clinical areas rather than being supplied with
the IMP
l Owing to total fluid volume per dose being reduced from 6ml to 5 ml, the amount of
lactoferrin in each individual dose was reduced to 375 mg so that the resulting solution
remained 75mg/ml as in the original application
l Inclusion of a Press-In Bottle Adapter in each container of IMP, compatible with oral syringes
l Updated the certificates and compliance statements included as appendices to the most
recent available versions
Consent form version 2 l Sections were added for the name of the participant from whom and hospital at which
consent was taken
PIL version 2 l Added the statement ‘We will keep your name, address and other contact details. The
Health and Social Care Information Centre and other central UK NHS bodies will be used to
keep in touch with you and provide information about your baby’s health status’
l Added the statement ‘Unidentifiable data from this study may be shared with other groups
who are carrying out similar work’ to cover anonymised data-sharing after the trial is over,
in line with the requirements of the funder
l Removed the word ‘independent’ in relation to the charity Bliss
ELFIN statement of
responsibilities version v1
l This document was introduced to describe the arrangements for recruiting, continuing care
and data collection sites
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Amendment
Date of REC
favourable
opinion
Date of
MHRA approval Document Description
Amend 2 3 January 2014 17 January 2014 IMP dossier version 3 l A provision for the use of non-automated filling of doses for up to 82 subjects for the pilot
phase of the trial. This is necessary because the auger filler to be used for automated filling
will not be installed and commissioned in time for the proposed start of recruitment
l A change to the HPLC assay for bovine lactoferrin
Amend 3 27 May 2014 – ELFIN/SIFT summary
leaflet version 1
l To add a joint summary leaflet to introduce both the ELFIN trial and SIFT to parents, where
recruitment to both trials is being considered (SIFT submitted an identical amendment to the
ethics committee)
Amend 4 11 July 2014 21 July 2014 – l Notification of temporary halt to trial. The circumstances leading to the temporary halt are
described fully in the amendment 4 covering letter
Amend 5 13 October 2014 3 November 2014 IMP dossier version 4 l Drug substance will be flushed with nitrogen when added to the hopper of the servo auger
filler machine
l Text for manual filling was amended to clarify that this process was used for batches
IMPNS4B002 and IMPNS4C001. Further batches will be manufactured by automated
process (using auger servo filler machine)
l Six sealed containers will be packed in a nitrogen-flushed, labelled aluminium pouch, lined
with polyethyltoluene and low-density polyethylene
l Four pouches of six containers (24 containers total) will be packed into one labelled
cardboard outer
l Based on the data presented in Table 2, maximum expiry will be limited to 2 years from
date of manufacture, assuming storage at ≤ 30 °C
l The stability testing programme will be conducted at 30 °C and 40 °C, in line with the
revised storage requirements of the product
GMP label version 2 l Storage requirements have been amended to ‘Store at or below 30 °C’. The original label
specified to store at or below 25 °C
Amend 6 29 October 2014 – NICU parent poster
version 1, antenatal ward
poster version 1
l Poster intended for viewing by pregnant women and/or their partners in antenatal areas
l Poster intended for viewing by parents in the neonatal unit
Amend 7 23 April 2015 – – l Addition of further recruiting sites in England
Amend 8 31 July 2015 – – l Addition of recruiting sites in England, Northern Ireland and Scotland
PIL version 3 l Added England/Northern Ireland/Scotland specific variants of version 3
l Updated contact details for the charity Bliss
l N.B. REC considered these changes non-substantial
Consent form version 3 l References PIL version 3 (Considered by REC to be non-substantial)
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Amendment
Date of REC
favourable
opinion
Date of
MHRA approval Document Description
Amend 9 10 September 2015 – – l Conversion of some continuing care sites in England to recruiting sites
Amend 10 – 16 December 2015 – l Removed requirement for temperature monitoring of IMP at continuing care sites
Amend 11 18 December 2015 31 December 2015 Protocol version 2.1 l Single change to protocol to remove requirement for research nurse reports to project
management group (not implemented as included in protocol version 3.0)
Amend 12 21 January 2016 – – l Conversion of additional continuing care sites in England to recruiting sites
Amend 13 8 March 2016 4 March 2016 Protocol version 3.0 l Section 4.7 describing existing RCTs of lactoferrin supplementation in preterm babies was
updated to reflect the recent 2015 Cochrane review68
l Section 7.2 was expanded to clarify that appropriately qualified and experienced neonatal
nurses may be delegated by the PI to assess eligibility
l Sections 7.8.1 and 7.8.2 were changed to clarify how doses of IMP should be calculated
against an infant’s current working weight and to better emphasise the pragmatic nature
of this trial
l Section 7.8.3 was added to clarify that independent nurse prescribers may be delegated by
the PI to prescribe IMP, provided this is consistent with local trust policy
l Section 7.10 was changed to reflect an updated procedure for unblinding a participant in
the event of an emergency
l Section 7.16 was changed so that the definition of end of trial is now the date at which the
trial database is locked
l Section 9.2 was added clarify the reference safety information to be used for the assessment
of adverse drug reactions
l Section 9.3.1 was changed to clarify that adverse events not meeting the criteria for
seriousness will not be collected for this trial
Amend 14 9 August 2016 – – l Added additional recruiting sites
l Change of some PIs at existing sites
Amend 15 22 November 2016 – – l Added a Wales-specific variant of ELFIN PIL version 3
l Added continuing care sites in Wales
l Change of some PIs at existing sites
Amend 16 6 September 2017 – – l Change of a PI at an existing site
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Amendment
Date of REC
favourable
opinion
Date of
MHRA approval Document Description
Amend 17 15 March 2018 15 March 2018 Protocol version 4.0 l The addition of a secondary outcome: microbiologically confirmed late-onset invasive infection
l Two secondary outcomes have been combined: total number of days of administration of
antibiotics administered per infant from 72 hours until death or discharge from hospital,
and total number of days of administration of antifungal agents per infant. The revised
secondary outcome is as follows: total number of days of administration of antibiotics or
antifungals (excluding prophylactic doses) from the commencement of dosing with the IMP
until 34 weeks’ postmenstrual age. The revised outcome more closely corresponds to the
period when the IMP bovine lactoferrin is administered
l An addition to the protocol to clarify that, if a participant is not discharged to home within
6 months (26 weeks) of the date of birth, data collection for that participant will be
completed at 6 months (26 weeks) from the date of birth
l Recruitment tables and graphs in appendix 4 were updated to reflect the actual recruitment
and date that recruitment to the trial ended
Amend 18 Pending Pending See protocol version 5.0
for track changes
l Submitted 27 June 2018
l Declaration NOT to conduct previously specified health economics analysis
HPLC, high-performance liquid chromatography; NICU, neonatal intensive care unit.
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Appendix 9 Withdrawals from intervention by
randomisation group
Reason
Trial group, n
Lactoferrin (n= 1099)a Placebo (n= 1104)a
Clinical decision 4 1
Consent remains (4) (1)
Consent completely withdrawn (0) (0)
Parental wish 15 14
Consent remains (15) (11)
Consent completely withdrawn (0) (3)
Otherb 1 0
Total 20 15
a Includes all infants randomised.
b Baby transferred to a hospital that refused to accept or administer the study intervention.
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Appendix 10 Group allocation per recruiting site
Centre
Trial group, n (%)
Lactoferrin (n= 1098) Placebo (n= 1101)
Jessop Wing, Sheffield 24 (2.2) 24 (2.2)
Royal Infirmary of Edinburgh 25 (2.3) 26 (2.4)
Princess Royal Maternity Hospital, Glasgow 26 (2.4) 27 (2.5)
Wishaw General Hospital 20 (1.8) 23 (2.1)
Royal Maternity Hospital, Belfast 20 (1.8) 20 (1.8)
James Cook University Hospital 76 (6.9) 70 (6.4)
Nottingham City Hospital 21 (1.9) 19 (1.7)
Queen’s Medical Centre, Nottingham 15 (1.4) 15 (1.4)
Birmingham Heartlands Hospital 16 (1.5) 14 (1.3)
Birmingham Women’s Hospital 52 (4.7) 54 (4.9)
Sunderland Royal Hospital 21 (1.9) 25 (2.3)
Altnagelvin Area Hospital, Londonderry 5 (0.5) 5 (0.5)
University Hospital Coventry 33 (3.0) 35 (3.2)
Royal Victoria Infirmary, Newcastle 68 (6.2) 66 (6.0)
University Hospital of North Tees 32 (2.9) 32 (2.9)
John Radcliffe Hospital, Oxford 15 (1.4) 17 (1.5)
Hull Royal Infirmary 17 (1.5) 17 (1.5)
Bradford Royal Infirmary 109 (9.9) 109 (9.9)
Calderdale Royal Hospital 10 (0.9) 10 (0.9)
Derriford Hospital, Plymouth 4 (0.4) 4 (0.4)
Great Western Hospital, Swindon 3 (0.3) 3 (0.3)
Leeds General Infirmary 83 (7.6) 82 (7.4)
Leicester Royal Infirmary 52 (4.7) 53 (4.8)
Norfolk and Norwich University Hospital 33 (3.0) 30 (2.7)
Pinderfields General Hospital, Wakefield 6 (0.5) 4 (0.4)
Princess Anne Hospital, Southampton 28 (2.6) 32 (2.9)
Queen Alexandra Hospital, Portsmouth 83 (7.6) 86 (7.8)
Royal Cornwall Hospital, Truro 15 (1.4) 12 (1.1)
Royal Devon and Exeter Hospital 13 (1.2) 9 (0.8)
Royal Hospital for Children, Glasgow 18 (1.6) 20 (1.8)
Royal Preston Hospital 16 (1.5) 15 (1.4)
Singleton Hospital, Swansea 14 (1.3) 12 (1.1)
St George’s Hospital, London 30 (2.7) 32 (2.9)
St Peter’s Hospital, Chertsey 32 (2.9) 32 (2.9)
William Harvey Hospital, Ashford 26 (2.4) 29 (2.6)
York Hospital 15 (1.4) 15 (1.4)
Victoria Hospital, Kirkcaldy 22 (2.0) 23 (2.1)
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